BIOTECHNOLOGY

Nov 13, 2026

Cellectis announced a potential global workforce reduction of up to 70%, affecting around 160 employees, as it transitions from allogeneic CAR T cell therapies to focus on in vivo gene editing. The company has halted enrollment in its CAR T programs to concentrate on its HEAL-101 and HEAL-201 in vivo candidates, which target severe hypertriglyceridemia and hypercholesterolemia, respectively. This strategic shift is expected to fund operations into the second half of 2028 and deliver initial clinical data for its in vivo programs in 2027 and 2028.

Nov 13, 2026

Regeneron Pharmaceuticals announced positive Phase 2 PINNACLE trial results for its investigational antibody, baloncibart, in treating postural orthostatic tachycardia syndrome (POTS). The drug significantly reduced abnormal standing heart rate spikes and improved various orthostatic symptoms, physical functioning, and daily living activities in patients. The 450 mg dose showed sustained benefits, confirming plasma volume expansion and a good safety profile.

Nov 13, 2026

Vertex Pharmaceuticals (NASDAQ: VRTX) has significantly outperformed the market over the last decade, with an annualized return of 19.42%. An investment of $1000 in VRTX stock ten years ago would now be worth $5,947.94, highlighting the substantial impact of compounded returns. The company currently holds a market capitalization of $137.57 billion.

Nov 13, 2026

Novo Nordisk has filed for approval of its oral pyruvate kinase-R (PKR) activator, etavopivat, for sickle cell disease (SCD) with both the FDA and EMA. This move positions Novo Nordisk in direct competition with Agios Pharmaceuticals, whose own candidate, mitapivat, recently experienced a delay in its FDA decision. The article highlights the intensifying race to market an oral PKR activator for SCD between the two pharmaceutical companies.

Nov 13, 2026

Moderna's shares fell after its 2026 Analyst Day, where it outlined a cost outlook for 2027 and beyond, but provided limited visibility into future revenue growth. While oncology, particularly its personalized cancer therapy intismeran autogene with Merck, is highlighted as a key long-term growth driver, investors were concerned by the projected spending without a clear revenue forecast. The company also continues to expand its infectious disease vaccine portfolio and expects 2026 revenues to grow 15-25%.

Nov 13, 2026

Moderna's shares fell after its 2026 Analyst Day, where the company highlighted oncology as a key long-term growth opportunity and outlined cost expectations for 2027 through 2030, but provided limited visibility into future revenue growth. The company is advancing a personalized cancer therapy with Merck and expanding its infectious disease vaccine portfolio. Despite a projected 15-25% revenue growth for 2026, investors were concerned about the lack of specific revenue forecasts for subsequent years amidst significant planned investments in oncology.

Nov 13, 2026

Rezolute Inc. (NASDAQ: RZLT) shares rose significantly in premarket trading following positive preliminary results from its Phase 3 upLIFT study for ersodetug in tumor hyperinsulinism. The study achieved its primary efficacy endpoint, with a high proportion of patients showing a significant reduction in glucose infusion rate. This positive news comes despite the company concurrently pricing a $100 million public offering.

Nov 13, 2026

Regeneron Pharmaceuticals is preparing to launch a Phase 3 trial in the first half of 2027 for its investigational monoclonal antibody, baloncibart (REGN7544), after successful mid-stage results in postural orthostatic tachycardia syndrome (POTS). The Phase 2 Pinnacle trial showed that a single 450-mg injection significantly reduced orthostatic heart rate and improved physical functioning for POTS patients. This development is significant as there are currently no FDA-approved treatments for POTS, a chronic condition causing abnormal heart rate elevations and other debilitating symptoms.

Nov 13, 2026

Cellectis is undergoing a major pivot from allogeneic CAR-T therapies to in vivo gene editing candidates, which will result in a 70% reduction of its global workforce by 2027. The company scrapped its clinical-stage CAR-T programs due to a changing commercial and clinical landscape and is now focusing on two preclinical in vivo candidates, HEAL-101 and HEAL-201, with clinical trials expected to begin in China in 2027 and 2028, respectively. This strategic shift aligns with a broader industry trend among cell therapy companies and Big Pharma towards in vivo approaches.

Nov 13, 2026

MediciNova (MNOV) reported a Q3 loss of $0.06 per share, which was in line with the Zacks Consensus Estimate but missed revenue estimates at $0.14 million. The biopharmaceutical company has surpassed EPS estimates twice and revenue estimates once in the last four quarters. The stock currently holds a Zacks Rank #3 (Hold), indicating it's expected to perform in line with the market.

Nov 13, 2026

Vir Biotechnology's stock fell in Friday's premarket trading after the company announced a $150 million public stock offering at $10 per share, raising concerns about shareholder dilution. Despite this short-term bearish pressure, the company has reported positive Phase 3 results for its hepatitis delta combination treatment and received FDA Fast Track designation for a prostate cancer candidate, with analysts maintaining a consensus Buy rating. The stock has seen significant gains over the past year, reflecting a mixed technical outlook.

Nov 13, 2026

Nanobiotix shares are experiencing a modest decline at midday but still show a substantial 36.87% gain over the past month, following a sharp recovery in recent weeks. The Paris-based oncology nanomedicine biotech is preparing for two meetings with the financial community in London, organized by Jefferies and UBS, on November 16 and 17. The company's first-half 2026 results indicated cash reserves of €110.9 million, sufficient to fund operations until 2029.

Nov 13, 2026

PDS Biotechnology (PDSB) reported a net loss of $7.6 million, or $0.11 per share, for the third quarter ended September 30, 2026. The company's operating expenses decreased to $5.9 million from $8.1 million a year earlier, and they announced an initial closing of a PIPE financing of up to $22.3 million led by Nant Capital. Additionally, 36 institutional investors increased their holdings in PDSB stock during the recent quarter.

Nov 13, 2026

Immunic Inc. CEO Erik Lundgren provided an update on the company's Q3 2026 performance, highlighting the anticipated topline results from the ENSURE-1 and ENSURE-2 trials for relapsing multiple sclerosis (MS) in December 2026. The company plans to submit a New Drug Application (NDA) in mid-2027 and expects to begin a third Phase 3 trial, PROTECT-MS, for progressive MS in the first half of 2027. Immunic's strong cash position of $132 million is expected to fund operations into late 2027, with additional funding potential from outstanding warrants.

Nov 13, 2026

Altimmune (ALT) reported a wider-than-expected loss of 15 cents per share in Q3 2026, with no revenues generated. The company's R&D and general and administrative expenses significantly increased, leading to investor concerns. Shares of ALT dropped nearly 17% following the announcement, reflecting worries over rising clinical development costs and funding uncertainty for its phase III AUD program.

Nov 13, 2026

This article from Stock Traders Daily analyzes Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM), highlighting key technical signals and institutional trading strategies. It presents three distinct AI-generated trading plans—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis suggests a prevailing positive sentiment in the near and mid-term, with a potential mid-channel oscillation pattern in play.

Nov 13, 2026

Kura Oncology, Inc. (NASDAQ:KURA) recently released its third-quarter results, showing a 9.3% rise in shares despite revenues coming in 4.4% below estimates. Analysts have updated their forecasts, now expecting revenues of US$199.0m in 2027, a 151% improvement, but also an increase in projected losses. The consensus price target remains unchanged at US$31.85, suggesting that the weaker earnings outlook may not impact long-term valuation.

Nov 13, 2026

Regeneron has reported positive Phase 2 data for baloncibart in postural orthostatic tachycardia syndrome (POTS), a nervous system disorder. The anti-NPR1 antibody showed a significant reduction in heart rate change in POTS patients compared to placebo, meeting its primary endpoint. Based on these results, Regeneron plans to initiate a pivotal Phase 3 trial in early 2027 for a condition that currently lacks FDA-approved treatments and affects millions.

Nov 13, 2026

Madrigal Pharmaceuticals (NASDAQ: MDGL) announced its participation in fireside chats at three upcoming investor conferences: the Jefferies Global Healthcare Conference, the Evercore Healthcare Conference, and the Piper Sandler Healthcare Conference. These webcasts will be accessible live on Madrigal’s Investor Relations Events page. The company will discuss its focus on novel therapeutics for MASH, including its FDA and European Commission approved medication, Rezdiffra.

Nov 13, 2026

Rezolute, Inc. (NASDAQ: RZLT) announced that 13 out of 16 participants in its Phase 3 upLIFT study for tumor-related hypoglycemia responded to ersodetug, with 12 stopping intravenous glucose entirely. The company expects the final statistical analysis by mid-December 2026 and is conducting an underwritten offering aiming to raise approximately US$100 million. Despite missing the primary endpoint in a separate congenital hyperinsulinism trial, Rezolute anticipates FDA discussions for ersodetug in the first quarter of 2027.

Nov 13, 2026

Agios Pharmaceuticals (AGIO) recently provided a third-quarter earnings update and news on its mitapivat regulatory review, showing a mixed performance with a 16.85% year-to-date gain but a 25.34% one-year decline. Analysts on Simply Wall St suggest the stock is 31% undervalued, with a fair value of $46.00 against a $31.76 close, primarily due to expectations for mitapivat's growth and pipeline assets. However, a high P/S ratio of 13.5x compared to an industry average of 10.3x indicates potential valuation risk if market sentiment shifts.

Nov 13, 2026

Candel Therapeutics Inc. (NASDAQ: CADL) saw its shares drop 39.09% in after-hours trading after reporting a wider net loss of $21.9 million for the third quarter of 2026. The company also announced a revised timeline for its prostate cancer regulatory application, now expected in mid-2027 pending FDA discussions. Despite the setback, Candel Therapeutics expressed confidence in its operational plan, stating its cash reserves are sufficient into Q2 2028.

Nov 13, 2026

Molecular Partners AG announced it will present its latest developments and outlook at the Inaugural UBS Global Biopharma Conference in London on November 16-17, 2026. CEO Patrick Amstutz will present on November 17 at 8 am GMT. The company, a clinical-stage biotech, is developing DARPin therapeutics for cancer patients, focusing on targeted radiotherapeutics.

Nov 13, 2026

Codexis Inc. reported a significant revenue increase of 124% year-over-year in Q3 2026, reaching $19.3 million, driven by growth in its biocatalysis business and progress in its ECO Synthesis platform. Despite continued net losses, the company strengthened its financial position with an equity offering and a term loan, extending its cash runway through 2028. Codexis is also seeing increased interest and engagement from biopharma and CDMO partners for its enzymatic synthesis technology, particularly concerning stereochemistry control and scalability.

Nov 13, 2026

DiaMedica Therapeutics (NASDAQ:DMAC) recently reported its Q3 2026 financial results, showing an increased net loss and higher research spending as it advances three clinical programs. The company has completed enrollment for the first two cohorts of its Phase 2 fetal growth restriction trial and expects an interim analysis for its ReMEDy2 Phase 2/3 acute ischemic stroke trial in Q1 2027. Investors are advised to monitor the upcoming preliminary results event on November 24, 2026, the ReMEDy2 interim analysis, and future financing announcements, given the company's declining cash balance.

Nov 13, 2026

Lineage Cell Therapeutics has acquired NeuroAirmid Therapeutics and its clinical-stage program, HUNT1, for Huntington's Disease. This acquisition adds a third clinical asset to Lineage's pipeline, aligning with their manufacturing capabilities. The HUNT1 program is currently in a Phase 1b/2a clinical trial, REGEN4HD, supported by the California Institute for Regenerative Medicine, with 6 patients already dosed.

Nov 13, 2026

Praxis Precision Medicines hosted its Investor Day, detailing launch readiness for relutrigine in SCN2A and SCN8A DEEs and ulixacaltamide in essential tremor, with PDUFA target action dates in late 2026 and early 2027. The company also unveiled plans to expand ulixacaltamide into Parkinson’s disease, Restless Legs Syndrome, and Autism Spectrum Disorder, alongside a broadened pipeline in pain and rare epilepsies. These strategic moves aim to position Praxis as a leading CNS biopharmaceutical company.

Nov 13, 2026

Dianthus Therapeutics EVP Ryan Savitz sold 2,561 shares of DNTH stock for approximately $230,849, reducing his direct holdings by 8.04%. This sale follows several other significant transactions by Savitz in early November. Despite the insider selling, DNTH shares rose 3.6% to $92.48, and the company reported a narrower-than-expected quarterly loss and revenue that exceeded analyst estimates.

Nov 13, 2026

Dianthus Therapeutics EVP Ryan Savitz sold 100,713 shares of the company's stock for approximately $9.12 million, significantly reducing his holdings. The company recently reported a quarterly loss of $0.81 per share, which was better than analyst expectations, and revenue of $1.21 million, exceeding estimates. Shares of DNTH traded up 3.6% following the news, and analysts maintain a "Buy" consensus rating with an average price target of $128.77.

Nov 13, 2026

Dianthus Therapeutics EVP Ryan Savitz sold 3,044 shares of the company's stock for $274,051.32 on November 11th, reducing his ownership by 9.42%. This sale is part of several recent transactions by Savitz, including larger sales totaling over $10 million in the days prior. Despite the insider selling, Dianthus Therapeutics shares traded up on Thursday, and the company recently beat quarterly earnings and revenue estimates, maintaining a consensus "Buy" rating from analysts with a target price of $128.77.

Nov 13, 2026

Xencor (NASDAQ:XNCR) Director Richard Ranieri sold 81,252 shares of the company's stock for approximately $3.19 million on November 10th, significantly reducing his stake. The sale comes after Xencor reported strong quarterly earnings, beating analyst estimates with $0.50 EPS and $116.52 million in revenue. Despite a "Moderate Buy" consensus rating and an average price target of $42.22, the stock fell 4.6% following the transaction.

Nov 12, 2026

Curis reported a third-quarter loss of $1.94 per share, beating consensus, but the improvement is largely due to significant share dilution. While the company achieved clinical progress with early PCNSL data and faster CLL enrollment, its cash reserves are critically low, funding operations only into early 2027, and the PCNSL filing timeline has slipped to 2028. Investors are balancing promising, but early, efficacy signals against the strong likelihood of further dilution before any potential drug approval.

Nov 12, 2026

Immix Biopharma (Nasdaq: IMMX) reported its Q3 2026 financial results, highlighting $340.9 million in cash and marketable securities, providing an operating runway into mid-2028. The company provided an update on its NEXICART-2 clinical trial for AL amyloidosis, showing an 89% complete response rate and plans for a BLA submission in mid-2027. Immix also announced key leadership appointments to strengthen its commercialization team and confirmed upcoming presentations at ASH 2026 and the J.P. Morgan Healthcare Conference.

Nov 12, 2026

PharmaCyte Biotech, Inc. (Nasdaq: PMCB) has announced a 1-for-19 reverse stock split, effective November 12, 2026, with trading on a post-split adjusted basis beginning November 13, 2026. This action is intended to increase the per share trading price of the common stock to meet Nasdaq's minimum bid price requirement. The reverse split will reduce the number of outstanding shares from approximately 10.7 million to 566,087, with proportional adjustments to outstanding stock options, warrants, and convertible securities.

Nov 12, 2026

MediciNova Inc. (MNOV) reported a third-quarter loss of $2.8 million, translating to 6 cents per share. The biopharmaceutical company, based in La Jolla, California, also posted revenues of $139,000 for the period. This financial summary was generated using data from Zacks Investment Research.

Nov 12, 2026

Compugen Ltd (CGEN) reported a doubling of revenue to $3.8 million in Q3 2026, driven by payments from its Gilead license agreement, while reducing its net loss to $5.8 million. The company's cash position of $117.5 million is expected to fund operations into 2029, and it anticipates over $1 billion in future milestone payments and royalties from partnerships with AstraZeneca and Gilead. Key clinical trials for COM701 and partnered programs are progressing, with significant data readouts expected by Q1 2027 and H2 2027, respectively.

Nov 12, 2026

Spero Therapeutics (SPRO) reported a net loss of $44.3 million, or $0.76 per diluted share, for the third quarter ended September 30, 2026, with no revenue. The company concluded the quarter with $107.9 million in cash, expected to fund operations until the second half of 2029, and plans a Phase 2 study for SP001 in 2027. Research and development expenses significantly increased to $38.2 million, while general and administrative expenses slightly decreased.

Nov 12, 2026

Pluri (NASDAQ: PLUR) has filed a $200 million mixed shelf offering, which could include common shares, preferred stock, warrants, and units. The company's stock currently has an overall analyst rating of "SELL."

Nov 12, 2026

MacroGenics (MGNX) reported a Q3 loss of $0.34 per share, significantly missing the Zacks Consensus Estimate of a $0.1 loss, and also failed to meet revenue expectations with $18.67 million against an estimated $61.99 million. Despite outperforming the S&P 500 year-to-date, the biopharmaceutical company holds a Zacks Rank #3 (Hold) due to mixed estimate revisions, suggesting it will perform in line with the market. Investors await management's commentary on the earnings call for insights into future stock movement.

Nov 12, 2026

Verrica Pharmaceuticals (VRCA) announced third-quarter 2026 revenue of $6.9 million, driven by record U.S. YCANTH net product sales of $5.7 million, an 11.9% increase quarter-over-quarter. Despite a net loss of $12.4 million, the company has completed enrollment for a pivotal Phase 3 common warts trial and expects topline data in early to mid-2027. Insider trading activity shows multiple purchases by executives, while institutional investors have mixed views, with some adding and others decreasing their positions.

Nov 12, 2026

Regeneron Pharmaceuticals (NASDAQ: REGN) has significantly outperformed the market over the past 15 years, achieving an average annual return of 21.73%. An initial investment of $1000 in REGN stock 15 years ago would now be worth $18,603.36, highlighting the power of compounded returns. The company currently holds a market capitalization of $99.25 billion.

Nov 12, 2026

Biomea Fusion, Inc. (Nasdaq: BMEA) announced that its management team will participate in several upcoming investor conferences, including the Jefferies Global Healthcare Conference, Citi's 2026 Global Healthcare Conference, and the Piper Sandler 38th Annual Healthcare Conference. The company will engage in fireside chats and one-on-one investor meetings at these events in November and December 2026. Biomea Fusion is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for diabetes and obesity.

Nov 12, 2026

Oragenics, Inc. announced that NYSE Regulation has approved its compliance plan, granting the company an extension until February 25, 2028, to regain compliance with NYSE American continued listing standards. This approval allows Oragenics to maintain its listing while implementing measures to strengthen its financial position and enhance shareholder value. The company, a clinical-stage biopharmaceutical firm, is developing neurological therapeutics, including ONP-002 for concussion and mild traumatic brain injury.

Nov 12, 2026

NuCana plc ADR (NCNA) experienced a 5.3% drop in share price, closing at $0.8900 due to persistent seller pressure and a lack of positive catalysts. The stock is trading below all major moving averages, with analysts noting weak technicals and the risk of further declines, though some suggest short-term volatility could create tactical opportunities for risk-tolerant investors. Key support is identified at $0.88, with momentum indicators confirming a bearish trend despite some oversold signals.

Nov 12, 2026

Artelo Biosciences reported a narrower loss for the third quarter of 2026, with a loss of $3.19 per share and a net loss of $1.8M. The clinical-stage biopharmaceutical company is advancing its development programs for therapeutics targeting lipid-signaling pathways. Wall Street analysts maintain a cautious outlook with no buy recommendations for the stock.

Nov 12, 2026

TScan Therapeutics reported third-quarter 2026 financial results, with a narrowed net loss of $33.1 million but a decrease in revenue to $0.6 million. The company announced a strategic shift to focus on in vivo-engineered T-cell therapies for solid tumors, leading to the pausing of enrollment in its Phase 3 ALLOHA-2 study due to insufficient capital. TScan is actively seeking partnerships for its blood-cancer and autoimmunity programs and expects its existing cash to fund operations into Q4 2027.

Nov 12, 2026

Exicure, Inc. has announced its 2026 Annual and Special Meeting for December 2, 2026, where stockholders will vote on six proposals. A key proposal seeks to double the company's authorized common shares from 200 million to 400 million, aiming to enhance capital structure and financing flexibility. Additionally, the company is seeking approval under Nasdaq Listing Rule 5635(d) to issue over 20% of its common stock in future private financing transactions.

Nov 12, 2026

Ocugen (NASDAQ: OCGN) anticipates pivotal data for its lead experimental gene therapy, OCU400 for retinitis pigmentosa, in Q1 2027, with a potential FDA filing in Q2 2027 and launch in Q4 2027. The company is also advancing treatments for Stargardt disease and geographic atrophy, expecting Q2 2027 results for Stargardt. Ocugen states its cash runway extends into 2028 but projects needing additional capital for commercialization.

Nov 12, 2026

This article analyzes Nurix Therapeutics Inc. (NASDAQ: NRIX), highlighting positive near-term sentiment amidst a weak mid-term and strong long-term context. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop levels. The analysis also details multi-timeframe signal strengths, support, and resistance levels for NRIX.

Nov 12, 2026

Estrella Immunopharma (NASDAQ:ESLA) experienced a 25.66% stock decline on November 12, 2026, dropping to USD 0.5902, despite no official quarterly report or specific catalyst being released around its anticipated reporting date. The clinical-stage biotech is developing T-cell therapies, with its lead candidate EB103 in a Phase I/II study for B-cell non-Hodgkin lymphoma. The company, which is pre-revenue and reported trailing net losses of USD 10.01 million, recently appointed a new CEO, and investors are keenly watching for patient data, financing terms, and Nasdaq compliance given its sub-$1 share price.

Nov 12, 2026

This article analyzes the fundamental and data-driven strengths of five healthcare stocks as of November 12, 2026. enGene (ENGN) is highlighted for its strong clinical trial results in bladder cancer, while Cumberland Pharmaceuticals (CPIX) is noted for its substantial cash reserves. Jin Medical International (ZJYL), Estrella Immunopharma (ESLA), and NextPlat (NXPL) are discussed with less favorable outlooks, primarily due to declining sales, early-stage development, or thin trading activity, respectively.

Nov 12, 2026

This article details five nano-cap companies scheduled to release earnings on November 13, 2026: SurgePays, Vistagen Therapeutics, Jaguar Health, Moving iMage Technologies, and Arrive AI Inc. It highlights their market capitalizations, EPS estimates, and recent financial performance or significant corporate actions. The piece also cautions readers that nano-cap shares can be volatile and trade thinly, advising against viewing the information as investment recommendations.

Nov 12, 2026

Mizuho Financial Group, Inc. has disclosed a 5.6% beneficial ownership stake in GalaxyEdge Acquisition Corporation, holding 901,705 common shares as of September 30, 2026. The Japanese parent holding company filed a Schedule 13G with the SEC, indicating sole voting and dispositive power over these shares, which are directly held by its subsidiary, Mizuho Securities USA LLC. The ownership is classified as passive, acquired and held in the ordinary course of business without the intent to influence control of the issuer.

Nov 12, 2026

Shares of Inovio Pharmaceuticals Inc. (INO) fell 1.02% to $1.46 on Thursday, underperforming the broader stock market, which also saw declines in the NASDAQ Composite and Dow Jones Industrial Average. The company's stock closed significantly below its 52-week high, reached on December 17th.

Nov 12, 2026

Kaplan Fox & Kilsheimer LLP is investigating Madrigal Pharmaceuticals (NASDAQ: MDGL) for potential securities law violations. This investigation follows a former employee's lawsuit alleging retaliation under the Sarbanes-Oxley Act, claiming the company retaliated after the employee raised concerns about data and reporting practices. The news of the lawsuit led to an 8.08% drop in Madrigal's stock price on November 3, 2026.

Nov 12, 2026

Eledon Pharmaceuticals (NASDAQ:ELDN) is expected to report a loss of $0.19 per share for the third quarter of 2026 when it releases results after market close on November 13, 2026. This projection follows a Q2 2026 net loss of $31.6 million ($0.27 per share). The clinical-stage company, valued at $216.97 million, had $88.8 million in cash and equivalents as of June 30, 2026, sufficient to fund operations into Q2 2027, and investors will be watching for updates on its Phase 3 kidney transplant study and financing plans.

Nov 12, 2026

Vivani Medical's stock surged after reporting positive Phase 1 clinical trial results for its semaglutide implant, NPM-139, which showed comparable weight loss to Wegovy without significant treatment-related side effects. The company plans to advance NPM-139 to a Phase 2 trial in 2027 and continues its collaboration with Novo Nordisk. Despite the positive news, Vivani Medical shares were down on Thursday at the time of publication.

Nov 12, 2026

This article lists 12 healthcare stocks that experienced significant price movements during Thursday's intraday session. It highlights six gainers, including Addex Therapeutics and enGene Therapeutics, with their respective percentage increases and stock prices. The article also identifies six losers, such as Estrella Immunopharma and SeaStar Medical Holding, detailing their percentage decreases and current stock values.

Nov 12, 2026

MediWound technically beat EPS estimates but missed revenue consensus by 53.2% and retracted its 2026 revenue outlook due to unpredictable U.S. government funding. While the company saw improvements in gross margin, NexoBrid demand, and government contracts, its near-term financial stability is compromised, and the balance sheet required fresh equity. Investors are now focused on the mid-2027 VALUE clinical trial readout and capacity expansion rather than immediate revenue figures.

Nov 12, 2026

Immix Biopharma, Inc. (NASDAQ:IMMX) is expected to report a consensus EPS of -0.19 for its third-quarter 2026 results on November 13, 2026, compared to a loss of 0.24 per share in the prior year. The company held USD 232.1 million in cash as of June 30, 2026, with an operating loss of USD 12.5 million for the April to June 2026 quarter, largely due to increased research and administrative costs. Immix Biopharma is advancing its NXC-201 trial and plans a BLA filing in the first half of 2027.

Nov 12, 2026

This article previews the earnings reports of five companies—Cosan S.A., Almonty Industries, Inhibrx Biosciences, Talon Metals Corp., and Immix Biopharma, Inc.—all due after market close on November 13, 2026. It highlights their respective EPS estimates, market capitalizations, cash balances, and recent financial performance. The report also touches upon key risks and future outlooks for each company.

Nov 12, 2026

Oragenics Inc. (OGEN) reported a loss of $2.6 million in its third quarter, resulting in a loss of 58 cents per share. The financial update was generated by Automated Insights using data from Zacks Investment Research.

Nov 12, 2026

Ascendis Pharma delivered a strong third-quarter performance, exceeding analyst estimates with significant earnings and revenue growth, driven primarily by its YORVIPATH product. The company reported solid profitability, generating operating leverage from its rare endocrine franchise, though a 42% non-IFRS operating margin was partly attributed to timing benefits rather than a sustainable new floor. While global sales of YORVIPATH are scaling and YUVIWEL is gaining traction, U.S. demand for YORVIPATH remains steady, and delays in a combination trial, an upcoming competitor, and reduced enrollment disclosure present some concerns for investors despite the positive financial results.

Nov 12, 2026

Regeneron Pharmaceuticals (REGN) shares have surged 27.4% in the past month, driven by strong third-quarter results from Eylea HD demand and Dupixent profit-sharing. Despite declining Eylea sales due to competition, Eylea HD and Dupixent's continued growth, along with an expanding oncology and rare disease portfolio, contribute to a positive outlook. Given its diversified growth drivers, promising pipeline, and favorable earnings outlook, Zacks Investment Research recommends REGN as a Buy.

Nov 12, 2026

Target Corp (TGT) is set to release its third-quarter earnings on November 18, with analysts expecting a significant year-over-year improvement in earnings per share and revenue. Options traders are taking bullish positions, indicated by a high call/put volume ratio, despite the stock's tendency to underperform volatility expectations. TGT has seen a 64% year-to-date gain and is testing support levels ahead of the report.

Nov 12, 2026

Acurx Pharmaceuticals reported a wider net loss of $2.6 million in Q3, missing consensus estimates despite a misleading per-share "improvement" due to significant share dilution. While the company began enrolling patients for its PATHFINDER trial earlier than expected, its financial position is precarious with only about 12 months of funding secured, growing capital market concerns, and increasing reliance on equity raises at depressed prices. The article highlights the tension between operational progress and financial challenges, emphasizing the need for financing or partnership news.

Nov 12, 2026

Absci reported a third-quarter loss that matched expectations, but revenue missed significantly. The company's hair-loss drug readout is now a key near-term catalyst in December, while the endometriosis program has been delayed. Rising R&D costs and a cautious tone around the hair-loss data suggest the December readout is critical for the stock's investment case.

Nov 12, 2026

Moderna presented its oncology-driven growth strategy at its 2026 Analyst Day, emphasizing its integrated mRNA platform for vaccines, individualized cancer therapies, and rare diseases. The company highlighted strong commercial growth opportunities, particularly in respiratory vaccines and with its lead oncology candidate, intismeran, which showed positive Phase III results in melanoma. Moderna also updated its financial outlook, projecting 15%-25% revenue growth and increased investment in oncology through 2030.

Nov 12, 2026

Revolution Medicines (RVMD) stock dropped 6.4% on November 11, 2026, despite a broader market rise, with many biotechnology peers increasing. The decline occurred after an earnings call revealed that initial sales of its new cancer drug, Daraxonrasib, were boosted by finite patient groups and initial inventory stocking, making the normalized launch trajectory unclear. The stock's valuation remains high at 196.6 times sales, and its operating loss widened in the third quarter.

Nov 12, 2026

Alnylam Pharmaceuticals (ALNY) stock rose 5.4% on Wednesday, November 11, 2026, while the broader S&P 500 gained 1.3%. This surge occurred despite the company not reporting earnings and followed a significant drop earlier due to management's dissatisfaction with demand growth and lower sales expectations for its TTR drugs. The gain helped Alnylam recover from a year-low, aligning with a wider market rally driven by eased worries about AI profits, though it still faces a substantial year-over-year decline.

Nov 12, 2026

Altimmune reported a net loss of $31.6 million for Q3 2026, driven by increased R&D expenses for its MASH Phase 3 and ALD Phase 2 trials. The company holds $480 million in cash and is pursuing non-dilutive funding. Altimmune is advancing pemvidutide for various liver diseases, with strong progress in its PERFORMA Phase 3 trial for MASH and positive Phase 2 results for AUD, leading to an upcoming FDA meeting.

Nov 12, 2026

Moderna Inc. (NASDAQ: MRNA) announced a strategic shift towards expanding its mRNA platform into multiple therapeutic areas, with a strong emphasis on oncology and rare genetic liver conditions, during its 2026 Analyst Day. The company raised its 2026 revenue growth forecast to 15% to 25% and detailed plans for commercial expansion, including the advancement of its individualized neoantigen therapy, intismeran, developed with Merck & Co., Inc. (NYSE: MRK). Moderna also highlighted enhanced manufacturing automation and robotics to reduce costs and accelerate turnaround times, securing improved terms on its credit facility and anticipating approximately $9 billion in total liquidity by the end of 2026.

Nov 12, 2026

Taysha Gene Therapies (NASDAQ: TSHA) reported a Q3 2026 net loss of $39.1 million, with increased R&D and G&A expenses due to clinical trials and commercial readiness. The company completed dosing in its REVEAL and ASPIRE trials for Taysha 102, with a favorable safety profile observed, and achieved a major manufacturing milestone for potential BLA submission in the first half of 2027. Taysha also plans to nominate a new gene therapy candidate for a CNS disorder in the first half of 2027 to expand its genetic medicines franchise.

Nov 12, 2026

Fennec Pharmaceuticals reported a record third quarter in 2026, with net product sales for Pedmark increasing 56% year-over-year to $19.4 million. The growth was driven by the expansion of its sales organization through "Project Ignite," leading to a 23% increase in patient enrollments and a 58% rise in infusions within the FENNEC HEARS program. The company also achieved record non-GAAP adjusted EBITDA of $5.8 million and generated significant cash from operations, while focusing on strategic initiatives like independent research and expanding market access for Pedmark.

Nov 12, 2026

MediWound reported a decrease in Q3 2026 revenue to $3.6 million, down from $5.4 million in Q3 2025, primarily due to reduced U.S. government development services revenue. Despite this, gross profit slightly increased to $1.0 million with improved margins. The company is on track to complete EscharEx Phase 3 VALUE trial enrollment by Q1 2027 and is actively discussing commercial partnerships for EscharEx, while expanding manufacturing capacity for NexoBrid due to strong demand.

Nov 12, 2026

EyePoint Pharmaceuticals reported disappointing Phase 3 wet AMD trial results, leading them to discontinue the program and reduce their workforce by 53%. The company is now focusing all resources on Duravu for diabetic macular edema (DME), which has shown promising Phase 2 data and a different biological profile from wet AMD. EyePoint ended Q3 2026 with $118 million in cash, expected to fund operations into late Q3 2027, and anticipates top-line results for the DME COMO and CAPRI trials in early Q4 2027.

Nov 12, 2026

MBX Biosciences CEO Steven Hoerter sold 4,893 shares of company stock for approximately $268,234 to cover tax withholding obligations on vested equity awards, retaining 78,045 shares. The company recently reported a quarterly loss of $1.29 per share, missing analyst expectations. Despite this, analysts maintain a "Moderate Buy" consensus rating with an average price target of $87.30, and institutional investors have been increasing their stakes.

Nov 12, 2026

Cormedix Inc. announced a definitive agreement to acquire Heron Therapeutics' assets, expecting to double their revenue base and achieve significant cost synergies by the end of 2027. For Q3 2026, Cormedix reported consolidated revenue of $54.5 million and adjusted EBITDA of $3.1 million, reaffirming 2026 revenue guidance and narrowing adjusted EBITDA guidance. The company is navigating uncertainties with DefenCath's 2027 reimbursement and advancing its pipeline, including FDA's priority review for REZZAYO's sNDA for prophylaxis.

Nov 12, 2026

Twist Bioscience reported strong Q4 2026 results with revenue up 28% year-over-year to $126.6 million, exceeding initial full-year guidance. The company achieved positive adjusted EBITDA of $2.2 million and saw significant growth in AI-enabled drug discovery revenue, which increased by 175% to $59.1 million. Twist Bioscience is expanding its manufacturing capacity and capabilities, with plans to invest $150 million in capital expenditures over fiscal 2027 and 2028, and forecasts fiscal 2027 revenue between $550 million and $560 million.

Nov 12, 2026

MeiraGTx Holdings PLC (MGTX) reported a Q3 loss of $0.53 per share, missing the Zacks Consensus Estimate of a $0.46 loss, though this was an improvement from a $0.62 loss a year ago. The company also missed revenue estimates, posting $4.81 million against an expected $6.87 million. Despite these misses, MGTX shares have gained 21.8% year-to-date, outperforming the S&P 500.

Nov 12, 2026

Acurx Pharmaceuticals (NASDAQ: ACXP) reported its third-quarter 2026 financial results and provided updates on its clinical trials, particularly the Pathfinder trial for recurrent C. diff infection, which is fully funded and enrolling patients. The company reported a net loss of $2.6 million for the quarter and $9.7 million in cash. Strategic initiatives include discussions with the FDA for Phase 3 trials, new patent approvals, and ongoing partnerships, with management expressing confidence in ibezapolstat's development and regulatory progress.

Nov 12, 2026

Moleculin Biotech, Inc. announced the grant of an Australian patent for the preparation of preliposomal Annamycin lyophilizate, further expanding its international intellectual property portfolio for the investigational cancer drug. This patent, jointly granted to Moleculin and The Board of Regents of The University of Texas System, covers a crucial aspect of Annamycin's formulation technology. The company continues to build a strong global IP position for Annamycin, which is currently in Phase 2/3 clinical trials for acute myeloid leukemia.

Nov 12, 2026

Moleculin Biotech (Nasdaq: MBRX) has secured an Australian patent for the preparation of the freeze-dried material used in its investigational cancer drug, Annamycin. This patent, jointly held with The Board of Regents of The University of Texas System, strengthens Moleculin's international intellectual property portfolio for Annamycin, which is being evaluated for acute myeloid leukemia and other difficult-to-treat cancers. The company's broader patent strategy also includes granted or allowed patents in ten other markets and pending applications in several other jurisdictions.

Nov 12, 2026

Can-Fite BioPharma Ltd. announced that its drug candidate, Piclidenoson, showed up to an 80% improvement in a kidney disease marker during a preclinical study for Lowe Syndrome. The findings from this study were published in a Nature Portfolio Journal, and the details were disclosed in a Form 6-K filing with the U.S. Securities and Exchange Commission on November 12, 2026. Certain paragraphs of the press release are incorporated into Can-Fite's existing Form S-8 and Form F-3 registration statements.

Nov 12, 2026

Vivani Medical (VANI) reported a net loss of $7.3 million for the third quarter ended September 30, 2026, with an increase in both research and development, and general and administrative expenses. The company anticipates top-line results from its SLIM-1 Phase 1 trial later this week and plans to submit an IND application for NPM-139 in 2027 for a Phase 2 study. Insider trading activity shows significant purchases by Gregg Williams, while institutional investors have mixed positions.

Nov 12, 2026

Moderna, Inc. outlined its next phase of growth at its 2026 Analyst Day, emphasizing the advancement of its mRNA platform into multiple modalities beyond infectious diseases, including oncology and rare genetic liver diseases. The company provided updates on commercial growth drivers like mFLUSIVA® and mCOFLU®, pipeline progress for intismeran in melanoma, and mid-term financial objectives including an expected 15% to 25% revenue growth for 2026. Moderna also highlighted the integration of AI and automation to enhance development efficiency and manufacturing productivity across its global production network.

Nov 12, 2026

MeiraGTx Holdings plc reported third-quarter 2026 revenue of $4.8 million and a net loss of $51.3 million. The company expects to submit a marketing authorization application for bota-vec in December 2026 and a U.S. biologics license application in Q1 2027. Insider trading activity showed sales by executives, while institutional investors had mixed activity, with some adding and others decreasing their positions.

Nov 12, 2026

Monopar Therapeutics (MNPR) reported a net loss of $6.2 million, or $0.72 per share, for the third quarter of 2026, an increase from a $3.4 million net loss in the prior-year quarter. The company expects its $129.4 million in cash and investments to fund operations through March 2028 and is progressing with its FDA New Drug Application for ALXN1840. Insider trading activity for MNPR shows 25 sales and no purchases in the last 6 months, while institutional holdings have seen significant additions and removals.

Nov 12, 2026

Belite Bio, Inc. (NASDAQ: BLTE) reported a strong liquidity position of US$774 million, comprising cash, cash equivalents, and U.S. Treasury holdings, ahead of the February 12, 2027, FDA target action date for its Stargardt disease drug, tinlarebant. The FDA has indicated it will not convene an advisory committee meeting for the application. The company also provided updates on its Phase 3 DRAGON trial results for tinlarebant and its geographic atrophy trial.

Nov 12, 2026

MEDIWOUND ($MDWD) announced its Q3 2026 earnings, reporting -$0.65 per share, surpassing analyst estimates by $0.07. However, the company's revenue of $3,570,000 fell short of expectations by over $3.2 million. The report also detailed recent insider trading activities and institutional investor movements in MDWD stock, along with current analyst price targets.

Nov 12, 2026

This article details the top health care stock gainers and losers in Thursday's pre-market session. Gainers include Addex Therapeutics and ZeroStack, while losers feature Basel Medical Group and Beyond Air, with several companies reporting recent earnings.

Nov 12, 2026

TScan Therapeutics (TCRX) reported Q3 2026 revenue of $0.6 million and a net loss of $33.1 million. The company announced a strategic reorganization focusing on in vivo-engineered TCR-T therapies for solid tumors, with cash resources expected to fund operations into Q4 2027. TScan also paused enrollment in the Phase 3 ALLOHA-2 study and is seeking partners for its heme malignancies and autoimmunity programs.

Nov 12, 2026

OKYO Pharma Limited announced its participation in the 2026 Jefferies Global Healthcare Conference in London from November 16-19, 2026. The company's leadership will be available for one-on-one investor meetings at the event. OKYO Pharma is a clinical-stage biopharmaceutical company focusing on treatments for neuropathic corneal pain and anterior segment eye diseases, with its lead candidate, urcosimod, currently in a Phase 3 trial.

Nov 12, 2026

FENNEC PHARMACEUTICALS ($FENC) announced its Q3 2026 earnings, reporting $0.12 per share, surpassing estimates by $0.03. The company also beat revenue expectations with $19,610,000. Insider trading activity showed four sales by executives in the past six months, while institutional holdings saw significant shifts, with some major firms adding shares and others reducing their positions.

Nov 12, 2026

Taysha Gene Therapies reported a narrower-than-expected third-quarter loss of $0.10 per share, driven by a drop in R&D spending after completing its process performance qualification (PPQ) manufacturing campaign for TSHA-102. While the company de-risked operational aspects and strengthened its balance sheet, the investment case now hinges entirely on the pivotal data and FDA feedback for TSHA-102 in the first half of 2027, with the potential for submission delays if the FDA requires 12-month data.

Nov 12, 2026

Fennec Pharmaceuticals reported its strongest commercial quarter, with adjusted EBITDA climbing to $5.8 million, raising its margin from 16% to 30%. Despite this strong profitability and record operating cash flow, the company faces moderating year-over-year revenue growth and has not provided formal guidance, leaving investors to weigh operating leverage against tougher comparisons. The stock's performance heading into the report was mixed, showing a rebound from a recent low but still below its August peak, indicating a neutral investor sentiment.

Nov 12, 2026

CorMedix (CRMD) reported a Q3 earnings beat, exceeding expectations for both loss per share and revenue, but faced a significant decline in its DefenCath revenue. The company is pivoting towards an acquisition-led diversification strategy with the Heron acquisition, aiming to offset the collapsing DefenCath franchise. Despite reaffirming full-year 2026 revenue guidance and raising Adjusted EBITDA guidance, the long-term outlook for DefenCath remains uncertain, and the market has reacted negatively to the withdrawal of 2027 DefenCath guidance and acquisition risks.

Nov 12, 2026

Altimmune reported a wider-than-expected third-quarter loss of $0.15 per share, attributed to increased spending as its lead asset, pemvidutide, entered a global Phase 3 trial for MASH. While clinical progress was made across multiple fronts, including the PERFORMA trial and a concrete plan for its AUD program, the rising costs and unsecured funding for the AUD Phase 3 trial are causing investor concern, leading to the stock trading near a 52-week low. The company faces scrutiny regarding enrollment numbers for PERFORMA and funding for the AUD program.

Nov 12, 2026

Alvotech (NASDAQ: ALVO) reported a third-quarter loss of $0.03 per share on revenue of $111.56 million, missing analyst estimates. While product and service revenue saw a significant year-over-year increase, licensing and other revenue declined, offsetting much of the gain. The company reaffirmed its full-year 2026 revenue and EBITDA guidance but now expects to land at the lower end of those ranges, placing significant reliance on a record-breaking fourth quarter.

Nov 12, 2026

Merck KGaA reported its Q3 2026 results and has raised its full-year guidance for the third time this year. This positive outlook comes as the German conglomerate is nearing completion of its $11.3 billion acquisition of U.S. life sciences firm Bio-Techne.

Nov 12, 2026

iBio (NASDAQ:IBIO) expects to release initial data from its clinical-stage myostatin program in the first quarter of the next calendar year and begin dosing patients in a separate Activin E study during the same period. The company anticipates initial human data from the Activin E study in the first half of the following year, which will primarily assess safety and pharmacokinetics. iBio has a cash runway into the second quarter of 2028 and may consider raising capital or partnering assets after clinical data becomes available.

Nov 12, 2026

iBio is advancing its obesity pipeline, expecting first-quarter data from its Phase 1 myostatin inhibitor IBIO-600 and initiating dosing in an Activin E antibody study during the same period. The Activin E study will focus on safety and pharmacokinetics, with potential future use alongside GLP-1 drugs for weight maintenance. The company states it has sufficient cash to fund operations until the second quarter of 2028.

Nov 12, 2026

Capricor Therapeutics filed its Q3 2026 earnings 8-K on November 10, just twelve days before the FDA's November 22 PDUFA date for deramiocel, its cell therapy for Duchenne muscular dystrophy. The filing itself is procedural, referencing a press release but not reproducing financial figures, though it confirms CEO Linda Marbán's sign-off. The key factor is the FDA's decision on deramiocel's approval and the scope of its labeled indication, which will determine its commercial reach.

Nov 12, 2026

ProQR Therapeutics N.V. (NASDAQ:PRQR) has received a "Moderate Buy" consensus rating from sell-side analysts, with an average 12-month price target of $7.60. The company recently surpassed quarterly earnings estimates, reporting a smaller loss per share and higher revenue than expected. Despite trading near its 52-week low, six out of eight analysts recommend buying the stock, reflecting positive sentiment toward the biopharmaceutical firm.

Nov 12, 2026

Roivant Sciences reported Q2 2026 revenue of US$35.12 million and a net loss of US$191.62 million, alongside the completion of a US$393.94 million share repurchase. The company's new drug, LISRIA, generated US$31 million in net revenue during its initial commercial weeks, supported by positive data from other clinical programs. The article examines how these developments, including early product uptake and clinical progress, are reshaping Roivant's investment narrative.

Nov 12, 2026

This article provides an analysis of Kymera Therapeutics Inc. (NASDAQ: KYMR) movements to inform risk allocation models, highlighting strong sentiment across all horizons. It presents three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each tailored to different risk profiles with specific entry, target, and stop levels. The analysis emphasizes an exceptional risk-reward short setup and provides multi-timeframe signal analysis for near-term, mid-term, and long-term horizons.

Nov 12, 2026

Stoke Therapeutics, Inc. (NASDAQ:STOK) has received a "Moderate Buy" consensus rating from eleven brokerages, with an average 1-year price target of $44.17. While the company's recent quarterly earnings reported a loss of $1.08 per share, missing estimates, its revenue of $11.26 million surpassed expectations. Insider transactions show recent sales by a director and an insider, but institutional investors have generally increased their holdings.

Nov 12, 2026

Kazia Therapeutics will host a virtual event on December 2, 2026, to discuss NDL2, its novel nuclear PD-L1 protein degrader. NDL2 is designed to combat immunotherapy resistance in advanced solid tumors, particularly metastatic breast and colorectal cancer, representing a potentially first-in-class approach in targeted protein degradation. The event will cover the scientific discovery and development of NDL2 and include a live Q&A session.

Nov 12, 2026

CorMedix Inc. (CRMD) reported a third-quarter loss of $14.7 million, or 19 cents per share. Adjusted for merger and acquisition costs, losses were 4 cents per share. The pharmaceutical and medical device company posted revenue of $54.5 million and expects full-year revenue between $325 million and $345 million.

Nov 12, 2026

MSCI has announced its November 2026 Equity Index Review, with changes effective after the close of November 30. Moderna (MRNA) will be added to the MSCI World Index. The article also mentions Canada's Aritzia (ATZAF) as another addition.

Nov 12, 2026

Xencor (XNCR) reported third-quarter 2026 net income but still shows a year-to-date net loss, highlighting the cost of its research programs. Initial Phase 1b data for plamotamab in rheumatoid arthritis demonstrated deep B-cell depletion and reduced disease activity, suggesting the company's bispecific platform could expand into autoimmune conditions beyond oncology. This early data is crucial for shaping the investment narrative and testing the platform's ability to produce differentiated autoimmune therapies in competitive fields.

Nov 12, 2026

This article provides a price-driven insight into Jazz Pharmaceuticals Plc (NASDAQ: JAZZ), highlighting strong sentiment across all horizons and an overweight bias. It outlines three distinct AI-generated trading strategies—Position Trading (LONG), Momentum Breakout (BREAKOUT), and Risk Hedging (SHORT)—with specific entry, target, and stop levels. The analysis emphasizes a mid-channel oscillation pattern and notes an exceptional risk-reward short setup.

Nov 12, 2026

This report from Stock Traders Daily provides an algorithmic analysis of Janux Therapeutics Inc. (NASDAQ: JANX), highlighting weak near and mid-term sentiment but a neutral long-term outlook. It details three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also identifies a significant 124.7:1 risk-reward setup targeting a 31.3% gain against 0.3% risk, along with multi-timeframe signal analysis and AI-generated support and resistance levels.

Nov 12, 2026

PepGen Inc. announced a proposed USD 125 million public offering of common stock and pre-funded warrants to fund clinical development of its lead myotonic dystrophy type 1 (DM1) therapy, PGN-EDODM1. This announcement followed positive Phase II FREEDOM2-DM1 results, showing significant muscle splicing correction and improvements in myotonia and mobility. The company reported USD 104.8 million in cash as of September 30, 2026, sufficient to fund operations into 2028 before the new offering.

Nov 12, 2026

MSCI will remove Strategy (MSTR) from its MSCI USA, World, and ACWI indices effective November 30, 2026, due to its new rule classifying the company as a "non-operating company" whose balance sheet is primarily bitcoin holdings. This decision will necessitate passive selling by index funds, estimated at around 3.1% of Strategy's outstanding shares or approximately $2.8 billion, though Strategy maintains the impact on its business will not be material. Investors holding MSCI World ETFs will see their funds automatically adjust, while direct shareholders will retain their shares, though the pool of automatic buyers will decrease.

Nov 11, 2026

This report provides a liquidity mapping analysis for Immunome Inc. (NASDAQ: IMNM), highlighting conflicting sentiment across different time horizons. It outlines three AI-generated trading strategies: a Position Trading Strategy (LONG), a Momentum Breakout Strategy (BREAKOUT), and a Risk Hedging Strategy (SHORT), complete with entry, target, and stop levels. The analysis also identifies key support and resistance levels across near-term, mid-term, and long-term perspectives.

Nov 11, 2026

This page provides the latest news and headlines for Madrigal Pharmaceuticals, Inc. (MDGL), including financial updates, analyst ratings, and performance data. Recent articles discuss the company's first profitable quarter, new real-world data for Rezdiffra, and its Q3 2026 earnings. The stock's performance data shows YTD and 1-year declines, but a significant 3-year gain.

Nov 11, 2026

Halozyme Therapeutics stock has dropped 21.5% recently, prompting investors to consider buying opportunities. Historically, a majority of similar past dips have led to gains for buyers a year later, though often after further initial declines. The company's royalty revenues are growing, and a patent dispute with Merck in Europe has favored Halozyme, though U.S. patent validity is still under appeal.

Nov 11, 2026

This article compares two healthcare ETFs: State Street SPDR S&P Pharmaceuticals ETF (XPH) and First Trust NYSE Arca Biotechnology Index Fund (FBT). XPH offers broader exposure to pharmaceutical companies with a lower expense ratio and a small dividend, making it suitable for long-term core holdings. FBT provides a more concentrated portfolio of biotechnology firms, has a stronger long-term performance record, but comes with a higher fee and no dividend, positioning it as a potentially riskier add-on for specific biotech exposure.

Nov 11, 2026

Viking Therapeutics (VKTX) has experienced a bullish reversal, targeting $43.55, following a post-earnings rally from $23.82 and the triggering of an inverse head-and-shoulders pattern above $28.00. The stock has a history of strong momentum, with a prior 1,100% rally, and current support was found at a significant prior resistance area. Further strength is anticipated with a reclaim of moving averages and a breakout above the consolidation range, potentially signaling the end of a longer-term correction.

Nov 11, 2026

Vivani Medical (Nasdaq: VANI) reported its financial results for the third quarter ended September 30, 2026, highlighting strong progress and anticipating top-line results for its SLIM-1 Phase 1 trial of NPM-139, a semaglutide implant for chronic weight management, later this week. The company also provided updates on its Cortigent-ClearOne merger and future milestones, including plans for a Phase 2 study of NPM-139 in 2027. Vivani aims to address medication non-adherence with its long-acting NanoPortal™ technology, which offers potential improvements in convenience, adherence, and reversibility compared to existing GLP-1 therapies.

Nov 11, 2026

PolyPid Ltd (PYPD) held its Q3 2026 earnings call, detailing the nearing FDA decision for D-PLEX100 with a PDUFA goal date of November 28, 2026, and ongoing labeling discussions. The company's partnership with Azurity has already yielded $30 million, with significant potential milestones remaining, and Azurity is preparing for a U.S. launch in early 2027. PolyPid also submitted an MAA to the EMA for D-PLEX100, with a decision expected in H2 2027 and a potential EU launch in 2028, and maintains a strong balance sheet to fund operations into 2028.

Nov 11, 2026

NuCana plc ADR (NCNA) shares dropped 1.6% to $0.92 due to technical selling pressure, with the stock trading below all key moving averages. Experts from Traders Union offer mixed outlooks, with some warning of further declines given deteriorating technicals and others seeing potential for a rebound if support holds. Overall, the technical signals are largely bearish, indicating weak momentum and persistent selling pressure.

Nov 11, 2026

Moderna announced the publication of real-world comparative effectiveness data for its mNEXSPIKE (COVID-19 Vaccine, mRNA) in adults aged 65 years and older. The study, published in JAMA Network Open, found that mNEXSPIKE was associated with 35.9% relative vaccine effectiveness against medically attended COVID-19 and 47.0% against COVID-19-associated hospitalization compared to Comirnaty. These findings highlight mNEXSPIKE's differentiated performance in vulnerable older adult populations, supporting its role in protecting against severe COVID-19 outcomes and major adverse cardiovascular events.

Nov 11, 2026

Novavax Inc. (NVAX) shares fell 2.16% to $9.98 on Wednesday, despite an overall positive trading session for the broader stock market. This marked the second consecutive day of losses for the stock. The NASDAQ Composite Index and Dow Jones Industrial Average both saw gains, rising 1.60% and 0.49% respectively.

Nov 11, 2026

Gossamer Bio reported mixed third-quarter financial results, with losses per share missing analyst estimates but sales exceeding expectations. Despite the mixed results and a subsequent 4.7% drop in shares, the company is focused on the potential launch of seralutinib in 2027 and the unlocking of additional committed capital. Following the earnings, analysts from Wedbush and Piper Sandler maintained their ratings but significantly lowered their price targets for the stock.

Nov 11, 2026

Latham & Watkins LLP advised Codexis, Inc. on a US$60 million senior secured term loan agreement with Trinity Capital Inc. Codexis, a provider of enzymatic solutions for therapeutics manufacturing, utilized the initial proceeds to retire existing debt. The Latham & Watkins team was led by New York partner Seniz Yakut, with significant contributions from various specialists across corporate, tax, UCC, intellectual property, data privacy, cybersecurity, and healthcare matters.

Nov 11, 2026

Beam Therapeutics (BEAM) announced positive top-line results from its phase I/II BEACON study for ristoglogene autogetemcel (risto-cel), an investigational gene-editing therapy for sickle cell disease. The study met its primary efficacy and safety endpoints, with plans to submit a biologics license application (BLA) to the FDA by the end of 2026. Despite these encouraging results, BEAM's shares declined 7%, possibly due to concerns over third-quarter results, profit-taking, and regulatory uncertainties.

Nov 11, 2026

Palisade Bio (NASDAQ: PALI) reported a wider-than-expected loss in the third quarter, missing analyst consensus estimates. Following the earnings announcement, analysts at HC Wainwright & Co. and Piper Sandler both lowered their price targets for the stock while maintaining their positive ratings. The company is advancing its clinical trials for PALI-2108, aiming for topline results in Q4 2027 for ASCENTRA-UC and initiating enrollment for ASCENTRA-CD in Q1 2027.

Nov 11, 2026

Eli Lilly's stock reached a 52-week high after announcing strong third-quarter growth driven by its GLP-1 agonists Mounjaro and Zepbound. In stark contrast, Alnylam Pharmaceuticals' stock hit a 52-week low on the same day as it reported its third-quarter results. Both companies are heavily reliant on dominant franchises, with Lilly's success attributed to its diabetes and obesity drugs, while Alnylam faced challenges.

Nov 11, 2026

Immutep Limited announced promising preliminary long-term survival data from its Phase 2 EFTISARC-NEO trial for soft tissue sarcoma, evaluating eftilagimod alfa with Keytruda and radiotherapy. The trial achieved an 81.1% disease-free survival rate at 12 months in evaluable patients. Additionally, the company secured a new U.S. patent protecting efti combination therapies through 2038.

Nov 11, 2026

Exicure Inc. (NASDAQ: XCUR) has agreed to sell its GPC-100 program assets to South Korea-based GPCRT Inc. for approximately $4.8 million. This transaction aims to strengthen Exicure's financial position and maximize stockholder value. The deal includes intellectual property, licensing rights, clinical records, and equipment related to GPC-100, also known as burixafor, which is used for stem cell mobilization.

Nov 11, 2026

Vertex Pharmaceuticals (VRTX) stock has outperformed the S&P 500 over the past year and faces several key events in the next six months that could significantly impact its share price. These include an FDA decision on povetacicept for IgA nephropathy, interim results for inaxaplin, its fiscal Q4 2026 earnings report, and proof-of-concept data for povetacicept in generalized myasthenia gravis. The company is also managing its patient support program for JOURNAVX, which affects the drug's net revenue.

Nov 11, 2026

Capricor Therapeutics Inc. (NASDAQ: CAPR) shares are trading higher despite reporting a wider-than-expected loss of 73 cents per share for the third quarter. The company announced significant progress on its regulatory filing and launch readiness for deramiocel, its Duchenne muscular dystrophy treatment, which has an FDA decision date of Nov. 22, 2026. The stock is up over 15% following these updates.

Nov 11, 2026

Legend Biotech's shares dropped 16% following its Q3 earnings report, marking a challenging start for new CEO Ingrid Zhang. Despite Carvykti's revenue growth, the company's CFO issued a conservative sales outlook for 2027, citing launch delays outside the U.S. and slower early-line market share growth in the U.S. This cautious forecast, along with competition in the multiple myeloma treatment landscape, dampened investor sentiment.

Nov 11, 2026

Jonathan Rose highlights three healthcare stocks—Prothena Corporation (PRTA), Rapport Therapeutics, Inc. (RAPP), and Azenta, Inc. (AZTA)—that have caught his attention due to insider purchases or corporate buybacks. While these actions signal confidence, Rose emphasizes that they are merely starting points for research, not immediate buy recommendations, and stresses the importance of further investigation into financial strength and catalysts. He details why each stock is on his watchlist, noting their balance sheets, upcoming clinical data, and growth outlooks, while also cautioning about the inherent risks in the biotechnology sector and market conditions.

Nov 11, 2026

Bruce C. Cozadd, a Board Member at Jazz Pharmaceuticals (NASDAQ: JAZZ), exercised stock options for 86,500 shares valued at $9,455,315, as disclosed in a recent SEC filing. The article also provides a company overview of Jazz Pharmaceuticals, focusing on its financial health, including revenue growth, gross margin, EPS, debt management, and various valuation ratios. It emphasizes the importance of insider transactions as part of a comprehensive investment analysis.

Nov 11, 2026

PolyPid's NDA for D-PLEX100 for surgical site infection prevention is under priority review by the FDA with a PDUFA goal date of November 28, 2026, and the company is preparing for a US launch in early 2027. The company also submitted a marketing authorization application to the EMA and plans for label expansion beyond colorectal surgery. Financially, PolyPid reported increased R&D expenses due to NDA activities but improved net loss, with cash reserves bolstered by a milestone payment from Azurity, extending funding into 2028.

Nov 11, 2026

PolyPid Ltd. reported $15.5 million in liquidity at quarter-end, with an additional $15 million partner payment arriving post-quarter, ahead of a crucial November 28 FDA goal date for its D-PLEX100 drug. The biopharmaceutical developer is focusing on preventing surgical site infections and expects a potential U.S. launch in early 2027, subject to approval, while also seeking a new European partner. Despite increased research and development expenses, the company's net loss narrowed for the quarter.

Nov 11, 2026

This report details precision trading strategies for Greenwich Lifesciences Inc. (GLSI), highlighting a mid-channel oscillation pattern and a significant short setup. It provides specific entry, target, and stop-loss levels for long position trading, momentum breakout, and tactical short-hedging strategies, alongside multi-timeframe signal analysis. The analysis notes stable neutral readings in shorter horizons, potentially signaling an easing of a long-term weak bias.

Nov 11, 2026

C4 Therapeutics (CCCC) saw its short interest increase to 38.09% of its float as of October 30th, up 9.03% from October 15th, totaling 46,580,600 shares. This indicates it would take short sellers approximately 15.14 days to cover their positions at current trading volumes. Additionally, the article highlights significant institutional investor activity, with 94 investors adding to their positions and 62 decreasing them in recent quarters.

Nov 11, 2026

Replimune Group (REPL) saw its short interest rise to 36.13% of the float as of October 30th, an increase of 6.23% from October 15th, according to new data from Benzinga. It would take an estimated 8.31 days for short sellers to cover their positions at current trading volumes. The article also details recent hedge fund activity, with 117 institutions adding and 120 decreasing shares, and highlights insider selling activity totaling 14 sales and no purchases in the last 6 months.

Nov 11, 2026

BridgeBio Pharma will present 28 abstracts on acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM) at the XX International Symposium on Amyloidosis (ISA) 2026. The data will highlight acoramidis's differentiated clinical profile, including its safety and efficacy in patients with chronic kidney disease, effects on cardiorenal function, and real-world outcomes compared to other treatments. These presentations aim to reinforce acoramidis as a leading first-line treatment option for ATTR-CM.

Nov 11, 2026

MINK THERAPEUTICS ($INKT) reported its Q3 2026 earnings, posting a loss of -$0.50 per share, which beat analyst estimates. However, the company's revenue of $200,000 fell significantly short of expectations. The article also details recent insider trading activity, showing three sales and no purchases, and highlights institutional investor changes in their holdings of INKT stock.

Nov 11, 2026

MiNK Therapeutics reported Q3 2026 financial results and provided a transcript from their earnings call. The company highlighted promising data from their iNKT cell therapies in cancer and severe lung injury, announcing a phase 2/3 trial for Agent 797 in ARDS. Financially, MiNK ended Q1 2026 with $9.5 million in cash, supported by non-dilutive partnerships and a disciplined capital approach.

Nov 11, 2026

Zacks Research has downgraded Arvinas (NASDAQ:ARVN) from a "strong buy" to a "hold" rating, though the overall analyst consensus remains "Moderate Buy" with a target price of $15.18. The company's recent quarterly earnings reported a beat on EPS at -$0.82 but significantly missed revenue expectations at $0.50 million, a 98.8% year-over-year decrease. Despite the downgrade, shares were up 2.4% on the day, opening at $6.92.

Nov 11, 2026

H.C. Wainwright analyst Douglas Tsao has reiterated a Buy rating and a $10.00 price target for Autolus Therapeutics plc (NASDAQ: AUTL). The full details of the analyst's report are available to premium subscribers.

Nov 11, 2026

Zacks Research has upgraded Keros Therapeutics (NASDAQ:KROS) to a "strong buy" rating, noting the company's strong quarterly performance where it significantly beat EPS and revenue estimates. The firm also authorized a $5 million share-repurchase plan. Despite an overall "Moderate Buy" consensus from analysts with an average price target of $21.40, Keros still faces some uncertainty regarding its path to profitability.

Nov 11, 2026

The iShares MSCI Taiwan ETF (EWT) allocates over 20% of its assets to Taiwan Semiconductor Manufacturing (TSMC), meaning a hypothetical $300,000 investment would have over $60,000 concentrated in this single chipmaker. While index rules prevent extreme concentration, this weighting means EWT's performance is heavily influenced by TSMC, which can lead to significant gains during booms but also substantial drops during downturns. Investors are advised to check the largest holdings of single-country funds to understand their true exposure.

Nov 11, 2026

NRx Pharmaceuticals has started selling its FDA-approved, U.S.-manufactured preservative-free ketamine through a new national sales force. The company expects high sales margins, with initial supply agreements targeted for late 2026 and shipments beginning in January 2027. This move aims to address a long-standing ketamine shortage since 2018 and offers a product free of benzethonium chloride (BZT), a preservative whose safety the FDA has not affirmed.

Nov 11, 2026

Absci Corp (NASDAQ:ABSI) is scheduled to release its Q3 2026 earnings on November 12, 2026, with revenue expected at $0.73 million and an earnings per share of -$0.20. While analysts project a 48.63% upside to an average price target of $14.82, GuruFocus estimates a 16.15% downside with a GF Value of $8.36. The average brokerage recommendation for Absci is "Outperform."

Nov 11, 2026

Arvinas, Inc. (Nasdaq: ARVN) announced its management will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026. The company is a clinical-stage biotechnology firm focused on targeted protein degradation to develop new drugs. A live audio webcast of the presentation will be available for interested parties.

Nov 11, 2026

PepGen Inc. reported positive topline results from the 10 mg/kg multiple ascending-dose cohort of its Phase 2 FREEDOM2-DM1 trial, showing a 46.5% mean splicing correction in DM1 patients and improvements in various physical function tests. The 12.5 mg/kg cohort is now fully enrolled. Despite a previous partial clinical hold by the FDA, the company's PGN-EDODM1 was selected for a CMC Development and Readiness Pilot program.

Nov 11, 2026

Ronald Todd Plott, a director at Phio Pharmaceuticals Corp., purchased 18,300 shares of the company's common stock at $0.83 per share on November 9, 2026. This transaction increased his direct beneficial ownership to 60,300 shares, including unvested restricted stock units. Phio Pharmaceuticals Corp. is a biopharmaceutical firm listed on NASDAQ under the ticker PHIO.

Nov 11, 2026

Amgen's Q3 2026 product sales relied heavily on six key growth drivers—Repatha, EVENITY, TEZSPIRE, and its oncology, rare disease, and biosimilar portfolios—which accounted for over 70% of sales and grew 27% year-over-year while other products declined. The company is advancing new products through its pipeline, including MariTide for obesity, and has raised its 2026 revenue guidance. Despite this, investors should monitor the continued growth of these six drivers, as Amgen's overall growth has slowed and its stock trades at a premium to the S&P 500, implying expectations for sustained rapid growth from these core products.

Nov 11, 2026

Harmony Biosciences Holdings Inc. reported a decline in third-quarter profit to $48.2 million, or 81 cents per diluted share, despite a 12% increase in sales of its narcolepsy treatment WAKIX, which generated $268.9 million. This profit fall was attributed to higher licensing costs and increased research and development spending. The company is reaffirming its full-year WAKIX revenue forecast and investing in experimental treatments like BP-205, while also defending its intellectual property.

Nov 11, 2026

Lipocine Inc. has announced that the first participant has been dosed in its BLOOM Phase 3 study for LPCN 1154, an oral brexanolone formulation for postpartum depression (PPD). This 48-hour oral treatment is designed for at-home use, with topline results from the 120-participant study expected in the second half of 2027. The study incorporates insights from a previous Phase 3 trial and FDA feedback to enhance site and data quality.

Nov 11, 2026

Immutep (ASX:IMM) has reported promising preliminary results from its EFTISARC-NEO Phase II sarcoma trial, showing an 81.1% 12-month disease-free survival rate in resectable soft tissue sarcoma patients. The trial also demonstrated high local recurrence-free and distant metastasis-free survival rates. Concurrently, the company secured a new US patent extending protection for efti-based combination therapies with PD-1 pathway inhibitors until March 2038.

Nov 11, 2026

Insmed (INSM) stock has shown high volatility with significant price swings, but its returns over the past five years have not adequately compensated investors for the extra risk compared to the S&P 500. The company, an unprofitable drugmaker, is in transition, with most of its revenue coming from BRINSUPRI and hopes for future profitability and new drug approvals. While Insmed's stock movements have largely been independent of the broader market, it adds specific risk related to new drug development rather than diversifying a portfolio.

Nov 11, 2026

Moderna's shares trade at a high multiple, indicating investor confidence in its pipeline beyond COVID vaccines, particularly a cancer treatment called Intismeran being developed with Merck. This treatment has passed a Phase 3 trial for melanoma and Moderna plans to file for approval in 2026. The company is funding this development through growing vaccine sales and a recent $3 billion convertible note, with the filing date for Intismeran being a key factor for investors to watch.

Nov 11, 2026

Genmab's petosemtamab, when combined with Merck's Keytruda, demonstrated a 50% reduction in death risk for head and neck cancer patients during a Phase 3 trial. This breakthrough highlights the growing importance of combination therapies in oncology. The article also touches upon the rise of agrivoltaics and Accenture's managed services business surpassing its consulting arm in revenue.

Nov 11, 2026

Kura Oncology reported a significant 53% sequential surge in KOMZIFTI net product revenue to $13.9 million in Q3 2026, driven by a 30% increase in new patient starts and 65% rise in total prescriptions. The company also secured up to $300 million in financing from Oberland Capital, strengthening its financial position, despite a decrease in collaboration revenue and a net loss of $70.2 million for the quarter. Kura Oncology maintains leadership in menin inhibitor new patient starts and plans for upcoming ASH presentations and a registrational study for darlifarnib.

Nov 11, 2026

Cabaletta Bio Inc. has granted stock options for 240,200 shares to four new non-executive employees as part of their recruitment compensation. These options, with an exercise price of $1.43 per share, are intended to incentivize new hires and will vest over four years. The biotechnology company, based in Philadelphia, is focused on developing cell therapies for autoimmune diseases.

Nov 11, 2026

Tyra Biosciences (NASDAQ:TYRA) stock dropped below its 50-day moving average after reporting a quarterly loss of $0.74 per share, missing analyst expectations of a $0.67 loss. Despite the earnings miss, analysts maintain a "Moderate Buy" consensus with an average price target of $47.20, although Oppenheimer lowered its target from $50 to $40. Institutional investors and hedge funds hold a significant 84.14% of the company's shares.

Nov 11, 2026

Prime Medicine, Inc. announced the pricing of an underwritten public offering of 35,714,286 shares of its common stock at $3.50 per share, aiming to raise approximately $125.0 million. The biotechnology company also granted underwriters a 30-day option to purchase an additional 5,357,142 shares. The offering is expected to close around November 12, 2026, with Jefferies, TD Cowen, and Goldman Sachs & Co. LLC acting as joint book-running managers.

Nov 11, 2026

Adaptive Biotechnologies COO Julie Rubinstein sold 11,881 shares of the company's stock on November 9th for a total of $357,855.72, bringing her remaining ownership to 377,802 shares. This transaction was part of a pre-arranged Rule 10b5-1 trading plan, and follows multiple similar sales throughout October and November. The company recently reported quarterly earnings that exceeded analyst expectations, with EPS of $0.02 and revenue of $83.9 million, despite a 10.7% year-over-year revenue decrease.

Nov 11, 2026

Coherus Oncology is reducing its workforce by 30% as part of a reorganization to focus its pipeline efforts primarily on esophageal cancer, deprioritizing other indications. Separately, Gyre Therapeutics is also undergoing layoffs following its acquisition of Cullgen, resulting in increased personnel and severance costs. Both biotechs are restructuring their operations, with Coherus aiming to significantly lower its quarterly core cash burn.

Nov 11, 2026

Humacyte reported a Q3 2026 earnings beat, with a loss of $0.06 per share against an expected $0.09, and revenue up 36.5% year-over-year to $1.0 million, driven by strong sequential growth in its Symvess vascular graft product. While the company remains unprofitable with negative gross margins, the significant acceleration in commercial adoption suggests potential market penetration. Investors are closely watching for sustained hospital adoption and improvements in manufacturing scale to achieve positive gross margins, which are critical for future profitability.

Nov 11, 2026

Cytokinetics announced new analyses from the ACACIA-HCM trial, showing that aficamten improved a broad quality-of-life score by 4.0 points over placebo in patients with non-obstructive hypertrophic cardiomyopathy. While the benefits were modest and require ongoing monitoring, these findings are significant as there is currently no approved medication specifically for this condition. Cytokinetics plans to seek FDA approval for aficamten for non-obstructive HCM in late 2026.

Nov 11, 2026

Insmed (NASDAQ: INSM) has significantly outperformed the market over the past five years, generating an average annual return of 31.4%. An initial investment of $1,000 in INSM stock five years ago would now be worth $3,750.47, highlighting the substantial impact of compounded returns.

Nov 11, 2026

Capricor Therapeutics (CAPR) saw its stock rally after hours as the company reaffirmed confidence in its Duchenne muscular dystrophy (DMD) therapy, deramiocel, during its third-quarter earnings call. The FDA is set to decide on deramiocel's approval for preserving upper-limb function in DMD patients by November 22, with Capricor stating its Biologics License Application is in final review. Despite a widened net loss and increased operating expenses, the company is advancing launch preparations and pursuing independent commercialization, while also reducing its workforce by 10%.

Nov 10, 2026

This article from Stock Traders Daily analyzes Enliven Therapeutics Inc. (NASDAQ: ELVN), indicating a strong sentiment across all horizons supporting an overweight bias. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop loss levels. The analysis highlights an exceptional 69.0:1 risk-reward setup targeting a 20.5% gain versus 0.3% risk.

Nov 10, 2026

Capricor Therapeutics reported a third-quarter loss of $0.73 per share, missing estimates, as pre-launch spending on Deramiocel climbed. The company enters a binary FDA decision on November 22, 2026, with a stronger data package but a narrower proposed indication for upper-limb impairment in patients over nine, following a previous negative advisory committee vote. This situation heightens the stakes for the upcoming FDA decision given accelerating spending and declining cash reserves.

Nov 10, 2026

Two local life sciences firms, Inovio and Orchestra BioMed, collectively raised over $172 million this week through public stock sales, with each company securing $86 million. Both firms successfully surpassed their initial fundraising targets for these offerings.

Nov 10, 2026

TG Therapeutics (TGTX) reported strong third-quarter 2026 results with robust revenue and slimmer profits, leading to a raised full-year revenue guidance of approximately US$1 billion. The stock has seen significant gains, with a 30-day return of 16.06% and a year-to-date gain of 119.47%, prompting investors to question its valuation. While a bearish narrative suggests the stock is overvalued at $64.26 compared to a fair value of $28.81 due to rising costs and pipeline spending, a discounted cash flow (DCF) model indicates it might be undervalued, trading 63% below an estimated future cash flow value of $172.03.

Nov 10, 2026

Editas Medicine is preparing to initiate a Phase I/II human trial for its gene-editing therapy, EDIT-401, targeting heterozygous familial hypercholesterolemia. The therapy previously achieved a 90% reduction in LDL cholesterol in nonhuman primates, an effect that lasted for 10 months. The company aims for over 60% LDL reduction in humans while prioritizing safety, with initial safety data expected in Q1 2027 and efficacy data in H2 2027.

Nov 10, 2026

Capricor Therapeutics is in the final stages of FDA review for its BLA for deramiocel, targeting upper limb impairment in Duchenne muscular dystrophy patients, with a PDUFA date of November 22, 2026. The company submitted a major amendment including 24-month open-label extension data from HOPE-3 and integrated efficacy data, reporting a net loss of $42.7 million for Q3 2026 due to pre-commercial activities. Capricor is preparing for commercial launch with a ready San Diego manufacturing facility and is managing a contractual dispute with NS Pharma.

Nov 10, 2026

NextCure, Inc. (Nasdaq: NXTC) provided a business update and reported third-quarter 2026 financial results, highlighting progress towards its proposed merger with Avere Therapeutics. The merger is now supported by approximately $820 million in committed financing, and the S-4 registration statement has been declared effective, with a stockholder vote scheduled for December 9, 2026. The company also detailed restructuring initiatives and its financial position, showing a net loss of $6.8 million for the quarter.

Nov 10, 2026

Inhibikase Therapeutics (IKT) reported a net loss of $20.5 million for the third quarter ended September 30, 2026, with $193.3 million in cash, cash equivalents, and marketable securities. The company's Phase 3 IMPROVE-PAH study of IKT-001 is progressing, having secured regulatory approvals in 28 countries and activated 79 clinical sites. Research and development expenses increased to $15.0 million, and the company sold 25 million common shares for $50 million in gross proceeds in July.

Nov 10, 2026

Palisade Bio (PALI) reported a net loss of $14.6 million in the third quarter of 2026, with cash and cash equivalents totaling $113.6 million. The company is advancing its PALI-2108 trial, having dosed the first patient in its Phase 2b ASCENTRA-UC trial and received FDA clearance for its Phase 2a ASCENTRA-CD trial. Insider trading activity for PALI stock shows more purchases than sales in the past six months, while institutional investors have largely increased their positions.

Nov 10, 2026

Exicure, Inc. has announced an agreement to sell its GPC-100 (burixafor) program assets to GPCRT Inc. for KRW 6.5 billion (approximately US$4.8 million). This sale, which includes intellectual property, clinical data, and related contracts, is part of Exicure's strategic evaluation to maximize stockholder value and improve its financial position. GPCRT will assume future obligations under the License and Collaboration Agreement, including milestone and royalty payments.

Nov 10, 2026

Kura Oncology announced strong third-quarter 2026 financial results, with KOMZIFTI net product revenue growing 53% sequentially to $13.9 million, driven by a 30% increase in new patient starts. The company also reached FDA alignment for a registrational study of darlifarnib in HRAS-mutated salivary gland cancer, targeting initiation in the first half of 2027. Kura Oncology secured up to $300 million in additional financing capacity and reported a strengthened cash position of $492.1 million.

Nov 10, 2026

Autolus Therapeutics announced longer-term follow-up data from its Phase 1 CARLYSLE trial of obe-cel in severe refractory systemic lupus erythematosus (srSLE), presented at ACR Convergence 2026. The data showed clinically significant improvements in SLEDAI-2K scores and DORIS achievement in most patients, alongside a favorable safety profile with no ICANS, IEC-HS, or high-grade CRS events. These results highlight obe-cel's potential as an important treatment option for autoimmune diseases.

Nov 10, 2026

Xilio Therapeutics, Inc. (XLO) reported a Q3 EPS of ($0.30), significantly beating the analyst estimate of ($0.92) by $0.62. The company's revenue for the quarter also exceeded expectations, coming in at $9.98 million against a consensus estimate of $5.74 million. This performance suggests a stronger financial quarter than anticipated by analysts.

Nov 10, 2026

Exicure has announced an agreement to sell its GPC-100 program assets to GPCRT Inc. for KRW 6.5 billion (approximately US$4.8 million). The sale, which includes license rights, intellectual property, and clinical data, is part of Exicure's ongoing evaluation of strategic alternatives. Spark, TipRanks’ AI Analyst, rates XCUR as "Underperform" due to weak financial fundamentals and a sustained downtrend.

Nov 10, 2026

Cognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates, which is a key indicator of potential stock price movement. The Zacks rating system highlights companies with improving earnings outlooks, suggesting a favorable impact on the stock price. This upgrade places CGTX in the top 20% of Zacks-covered stocks, indicating its superior earnings estimate revision feature and potential for market-beating returns.

Nov 10, 2026

Legend Biotech Corp (LEGN) announced strong Q3 2026 earnings, with CARVYKTI net trade sales increasing 36% year-over-year to $710 million, driven by significant growth outside the U.S. and accelerating earlier-line adoption. The company achieved adjusted net income of $55.6 million and improved its gross margin to 58%, remaining on track for full-year 2026 profitability. Despite U.S. sales flattening quarter-over-quarter and increasing competitive pressures from bispecifics, Legend Biotech remains confident in CARVYKTI's long-term growth potential and its robust pipeline.

Nov 10, 2026

Coastlands Capital LP has reported the acquisition of 50,000 common shares of Bolt Biotherapeutics (NASDAQ:BOLT) on November 9, 2026. The shares were purchased at a weighted average price of $6.38 each, increasing Coastlands Capital LP's indirect beneficial ownership to 462,416 shares. This transaction further solidifies Coastlands Capital LP's position as a 10% owner of Bolt Biotherapeutics.

Nov 10, 2026

Ocugen Inc. has expanded its international commercialization prospects for its experimental blindness gene therapy, OCU400, by securing a licensing agreement in the Middle East and North Africa potentially worth $259 million and receiving provisional regulatory approval in the Bahamas. These developments precede crucial Phase 3 clinical results for OCU400 expected in early 2027, along with upcoming readouts for other late-stage gene therapy programs, OCU410ST and OCU410. The company reported $84.6 million in cash, projecting operations into 2028, and is preparing for regulatory submissions and global partnerships.

Nov 10, 2026

Madrigal Pharmaceuticals Inc. reported its first profitable quarter, with net income of $55.4 million, driven by a 50% surge in sales of its liver disease treatment, Rezdiffra, to $431.3 million in Q3 2026. Rezdiffra's sales have already surpassed $1.1 billion year-to-date, reaching blockbuster status. The company is expanding its commercial operations and advancing clinical trials to extend Rezdiffra's use for more advanced stages of liver disease.

Nov 10, 2026

Beam Therapeutics announced positive topline pivotal data for risto-cel, its base-editing sickle cell therapy, which met the primary endpoint of freedom from severe vaso-occlusive crises for at least 12 months in the BEACON trial. This achievement positions Beam to submit a Biologics License Application to the FDA as early as the end of 2026, potentially marking the first base-editing therapy to reach this stage. While the company did not disclose the exact number of patients reaching the endpoint, detailed results are anticipated at a medical meeting in 2027, with earlier data presented at the American Society of Hematology meeting in December.

Nov 10, 2026

This report analyzes Denali Therapeutics Inc. (NASDAQ: DNLI) using AI-generated trading strategies. It highlights a near-term neutral sentiment amidst mid and long-term strength, noting a mid-channel oscillation pattern and an exceptional 52.0:1 risk-reward setup targeting a 16.1% gain. The analysis provides three distinct trading plans: Position Trading, Momentum Breakout, and Risk Hedging, complete with entry, target, and stop levels.

Nov 10, 2026

CRISPR Therapeutics AG presented clinical data for its investigational gene editing therapy, CTX310, showing significant reductions in lipid levels for patients with severe hypertriglyceridemia. A single course of treatment led to a 65% mean reduction in ANGPTL3 and a 63% mean drop in triglycerides at Day 30, along with favorable safety results. William Blair reiterated an Outperform rating, noting the data exceeded expectations and indicated preliminary regulatory buy-in.

Nov 10, 2026

PepGen's stock surged over 132% after the biotech company announced strong clinical trial data for its rare-disease treatment targeting myotonic dystrophy type 1. This significant development is putting pressure on rival companies that are also developing therapies for the same condition, which affects an estimated 1 in 8,000 people worldwide.

Nov 10, 2026

PepGen Inc. (NASDAQ: PEPG) saw its stock double after reporting positive topline results from its Phase 2 FREEDOM2-DM1 study for myotonic dystrophy type 1. The study showed significant splicing correction in muscle tissue and notable functional improvements in patients, with a favorable safety profile. These results position PepGen favorably amidst competitor developments in the sector.

Nov 10, 2026

Valneva SE reported positive five-year antibody persistence results for its single-dose chikungunya vaccine, IXCHIQ, demonstrating lasting immune protection across diverse age groups. Data from the VLA1553-303 trial showed 94% of participants maintained neutralizing antibody levels above the seroresponse threshold five years post-vaccination, with older adults showing comparable persistence. The company continues to collect real-world data in Brazil, although the vaccine's license was suspended in the U.S. due to serious adverse event reports.

Nov 10, 2026

BioNTech SE announced an agreement to acquire a U.S. FDA Priority Review Voucher (PRV) from Scholar Rock for $205 million. A PRV allows for expedited review of a single FDA application, potentially shortening approval timelines. Despite a strong balance sheet, TipRanks' AI Analyst, Spark, rates BNTX as "Neutral" due to a weaker earnings profile and pressured cash flow.

Nov 10, 2026

Black Diamond Therapeutics (NASDAQ: BDTX) reported updated Phase 2 data for its cancer drug silevertinib, showing promising antitumor activity in non-small cell lung cancer patients with EGFR mutations. Following a positive FDA meeting, the company plans to initiate a global Phase 3 trial in Q2 2027 and expects its current cash to fund operations into the second half of 2028. Despite the positive news, shares were down 13.49% at publication time.

Nov 10, 2026

Puma Biotechnology, Inc. published a slide deck for their 2026 Q3 earnings call, which was held on November 10, 2026. The article highlights that Seeking Alpha's transcripts team is responsible for developing and publishing thousands of quarterly earnings call transcripts. This particular release provides insights into the company's Q3 performance as detailed in the presentation.

Nov 10, 2026

Scholar Rock has agreed to sell its rare pediatric disease priority review voucher to BioNTech's U.S. unit for $205 million in cash. The FDA awarded the voucher in September when it approved Isembyld for spinal muscular atrophy. This sale price is near the top of the recent market for such vouchers, which allow for a six-month drug application review instead of the standard ten months.

Nov 10, 2026

This article compares Amgen and Regeneron as investment options for retirees, focusing on income, valuation, and growth. Amgen is favored for its higher and consistently growing dividend, suitable for those seeking immediate income. Regeneron, though, is highlighted for its stronger growth, lower valuation, and debt-free balance sheet, making it more appealing for investors with a longer time horizon focused on total return.

Nov 10, 2026

Humacyte, Inc. announced its Q3 2026 financial results, reporting a narrower-than-expected loss of $0.06 per share, beating analyst estimates. The company's revenue increased by 36.5% year-over-year to $1.0 million, driven by the commercial rollout and gradual uptake of its Symvess vascular graft product in 49 hospitals. Despite a net loss of $15.5 million due to expansion investments, analyst sentiment remains positive with a consensus of 6 buys and 2 holds.

Nov 10, 2026

BofA Securities analyst Tazeen Ahmad upgraded PepGen Inc. (PEPG) from Underperform to Neutral, setting a new price target of $6.00, up from $2.50. This upgrade led to an increase in the company's stock price and updated rating summaries from analysts. The report highlights PepGen's recent stock performance and analyst sentiment.

Nov 10, 2026

PepGen reported positive clinical results from its Phase 2 FREEDOM2-DM1 trial, showing a mean splicing correction of 46.5% in the 10 mg/kg cohort, the highest reported in a multiple-dose study for myotonic dystrophy type 1. The company also observed improvements in functional measures and reported that PGN-EDODM1 was generally well tolerated. Despite a partial FDA clinical hold, PepGen expects further results in the first half of 2027 and has sufficient cash to fund operations into 2028.

Nov 10, 2026

Beam Therapeutics announced positive topline data from its Phase I/II BEACON trial for ristoglogene autogetemcel (risto-cel), a cell therapy for sickle cell disease (SCD). The therapy successfully met its primary and secondary endpoints, demonstrating freedom from severe vaso-occlusive crises for at least 12 consecutive months. Based on these results, Beam plans to submit a biologics license application (BLA) to the US FDA by the end of 2026, aiming to be the first base editing therapy approved.

Nov 10, 2026

On November 10, 2026, several healthcare and biotech stocks experienced significant gains, with PepGen (NASDAQ:PEPG) leading the pack with a 159.83% increase, despite no identified catalyst. Other top performers included Autonomix Medical (NASDAQ:AMIX) up 51.76%, Nano-X Imaging (NASDAQ:NNOX) up 45.14%, Humacyte (NASDAQ:HUMA) up 28.08% on its results day, and Estrella Immunopharma (NASDAQ:ESLA) up 26.48%. The article notes that many of these gains occurred in small-cap, sub-dollar stocks with no clear catalyst, often in thinly traded names, which could be prone to reversal.

Nov 10, 2026

PepGen Inc. reported positive Phase 2 clinical data for PGN-EDODM1, its investigational treatment for myotonic dystrophy type 1 (DM1), showing significant RNA splicing correction and functional improvements in patients. The company ended Q3 2026 with $104.8 million in cash, expected to fund operations into 2028, despite a widening net loss of $19.4 million for the quarter. Future results from higher-dose cohorts and an open-label extension study are anticipated in early 2027, as PepGen works to address an FDA partial clinical hold.

Nov 10, 2026

PepGen Inc. (Nasdaq: PEPG) saw its stock surge by 148.49% on high volume after announcing positive topline data from its Phase 2 FREEDOM2-DM1 trial for myotonic dystrophy type 1 (DM1), showing a 46.5% mean splicing correction, the highest reported to date. The company also reported $104.8 million in cash and equivalents, projected to fund operations into 2028, and is advancing its PGN-EDODM1 program, with results from the highest dose cohort expected in the first half of 2027.

Nov 10, 2026

Biomea Fusion, Inc. announced its financial results for the third quarter ended September 30, 2026, reporting a net loss of $6.2 million. The company provided updates on its clinical programs, including completed enrollment for the Phase II COVALENT-211 trial and ongoing enrollment for COVALENT-212, both evaluating icovamenib for type 2 diabetes. Additionally, Phase I results for BMF-650, an oral GLP-1 RA for obesity, showed promising weight reduction and a favorable tolerability profile, with plans for a strategic partnership.

Nov 10, 2026

Kura Oncology reported strong third-quarter 2026 financial results, with KOMZIFTI net product revenue growing 53% sequentially to $13.9 million, driven by a 30% increase in new patient starts. The company also announced FDA alignment for a registrational study of darlifarnib in HRAS-mutated salivary gland cancer and secured up to $300 million in additional financing. Kura Oncology's financial position remains strong, with $492.1 million in cash, cash equivalents, and short-term investments, and anticipates continued investment in its precision oncology franchises.

Nov 10, 2026

Inhibikase Therapeutics reported its financial results for the third quarter ended September 30, 2026, highlighting significant progress in its Phase 3 IMPROVE-PAH study for IKT-001, with 28 country regulatory approvals and 79 clinical sites activated. The company also announced a $50 million capital raise from RA Capital Management and the appointment of Scott M. Wasserman, MD, to its Board of Directors. Inhibikase is further exploring IKT-001's potential through nonclinical studies for combination therapy with sotatercept and its application in Group 2 and Group 3 pulmonary hypertension.

Nov 10, 2026

Mirum Pharmaceuticals announced that its AZURE-4 Phase 3 trial for hepatitis delta met its primary endpoint, with 59% of weekly brelovitug recipients achieving combined viral and liver-enzyme responses. The company plans to file for FDA approval in the first half of 2027. This success follows a similar positive outcome in the AZURE-1 study and positions Mirum for a potential U.S. launch in late 2027.

Nov 10, 2026

Cellectar Biosciences reported a cash position of $24.6 million for Q3 2026, supported by a $140 million financing deal. The company is progressing its iopofosine I-131 program for Waldenstrom’s macroglobulinemia (WM), aiming for an NDA submission in H1 2027 and potential commercialization by late 2027 or early 2028. Key developments include the initiation of a confirmatory Phase 3 trial, a Phase 1b dosimetry study, and strategic delays in European market submission to optimize U.S. pricing.

Nov 10, 2026

Scholar Rock Holding (NASDAQ: SRRK) reported its Q3 2026 financial results, including $0.6 million in Isemble revenue and $413.6 million in cash. The company is actively launching Isemble in the US, with strong initial patient demand despite expected reimbursement and access delays, and is preparing for launches in Europe and Japan by late 2027. Scholar Rock also monetized a priority review voucher for $205 million, bolstering its financial position to fund global commercial and R&D initiatives.

Nov 10, 2026

Latham & Watkins LLP represented the placement agent in a US$30 million private placement for Abeona Therapeutics Inc. The biopharmaceutical company entered into a securities purchase agreement with investors for 6.4 million shares of common stock and pre-funded warrants. The transaction was led by San Diego partners Matt Bush and Anthony Gostanian.

Nov 10, 2026

Summit Therapeutics has lost its chief commercial officer, Robert LaCaze, and several other commercial and marketing leaders just before the FDA's decision on its drug, ivonescimab, for non-small cell lung cancer. The company downplayed the departures as routine while sources close to the company indicate that "long-term players" responsible for launch planning were let go. This comes as the FDA decision is uncertain, given the drug's global HARMONi trial missed its overall survival endpoint.

Nov 10, 2026

Autolus Therapeutics reported strong Q3 2026 financial results with obe-cel net revenues of $41.2 million, a 95% increase year-over-year, and raised its full-year revenue guidance to at or above $150 million. The company achieved a positive gross margin of 57% and expanded its US activated centers to 90, exceeding its initial target. Autolus also provided updates on its clinical pipeline, including ongoing trials for obe-cel in multiple sclerosis and lupus, and upcoming data presentations at ACR and ASH.

Nov 10, 2026

PepGen Inc. reported positive Phase 2 results for its DM1 trial, showing an average of 46.5% splicing correction in six treated patients and functional improvements in hand opening and grip strength. The company maintains a strong cash position but faces a partial FDA clinical hold, which needs to be resolved before an end-of-Phase 2 meeting can occur in the second half of 2027. Further extension data is expected in January 2027.

Nov 10, 2026

Legend Biotech reported strong Q3 2026 financial results, with CARVYKTI net trade sales increasing 36% year-over-year to $710 million, driven by U.S. adoption in earlier lines and international expansion. The company aims for company-wide profitability in 2026 on an adjusted net income basis, supported by a robust cash position and advancements in its next-generation cell therapy pipeline, including FDA clearance for LB2501. Management emphasized maximizing CARVYKTI's potential, particularly in earlier treatment settings, and disciplined execution to ensure sustained growth and profitability.

Nov 10, 2026

This article highlights three biotech companies—Regeneron, Amgen, and Royalty Pharma—that defy the industry's reputation for burning cash by consistently paying and raising dividends. It details each company's dividend yield, payout safety through earnings or free cash flow, recent dividend increases, and bull and bear cases. The piece emphasizes that these companies generate sufficient revenue from approved drugs or royalties to provide quarterly returns to shareholders.

Nov 10, 2026

State Street Corporation has disclosed a 4.7% beneficial ownership stake in MannKind Corporation, as detailed in a Schedule 13G filing with the SEC. As of September 30, 2026, State Street holds 15,096,712 shares of MannKind common stock through five investment adviser subsidiaries. The filing indicates shared voting power over 14,316,800 shares and shared dispositive power over all 15,096,712 shares, with the acquisition made in the ordinary course of business.

Nov 10, 2026

Protalix BioTherapeutics reported strong financial results for Q3 2026, with revenues reaching $21.9 million, an increase from $17.9 million in Q3 2025, primarily due to higher Elfabrio sales. The company achieved a net income of $4 million and maintained a healthy cash position of $48.5 million with no debt. Protalix is focused on expanding Elfabrio's market presence and advancing PRX115 for uncontrolled gout, which is currently in a Phase 2 study with promising Phase 1 data.

Nov 10, 2026

PolyPid (NASDAQ: PYPD) is nearing a significant FDA decision for its D-PLEX100 product, aimed at preventing surgical-site infections, with a target date of November 28. The company has a U.S. commercialization agreement with Azurity Pharmaceuticals and is actively seeking new European partnerships, having recently regained European rights. Additionally, PolyPid is advancing PD01B, a second pipeline product leveraging its Kynatrix technology to treat diabetic foot infections, highlighting multiple avenues for future growth.

Nov 10, 2026

Verrica Pharmaceuticals Inc. announced that its President and CEO, Jayson Rieger, PhD, MBA, will present at the Jefferies Global Healthcare Conference in London on Thursday, November 19, 2026, at 1:30 PM GMT. The company, focused on dermatological disease treatments, will provide a live webcast of the event on its investor relations website, with a replay available for 90 days afterward. Verrica is known for YCANTH® (VP-102) for molluscum contagiosum and is developing treatments for common warts and non-melanoma skin cancers.

Nov 10, 2026

Humacyte reported a 151% increase in Synvest sales for Q3 2026, reaching over $1 million, and expects to double sales in Q4. The company is preparing to submit a supplemental Biologics License Application (sBLA) for its ATEV product for dialysis access and has initiated a Phase 2a clinical study for Coronary Tissue Engineered Vessels (CTEV) for coronary artery bypass grafting. Despite a net loss of $15.5 million in Q3 2026, Humacyte saw an improvement from the previous year and is optimistic about future growth driven by its commercial strategy and pipeline progress.

Nov 10, 2026

Moderna, Inc. (Nasdaq: MRNA) announced its participation in the Jefferies Global Health Care Conference on Wednesday, November 18th, 2026, at 11:00 AM GMT. A live webcast of the presentation will be available on Moderna's investor relations website, with a replay archived for at least 30 days. The company, a leader in mRNA medicine, will highlight its advancements in vaccines and therapeutics across various diseases.

Nov 10, 2026

Cullinan Therapeutics (Nasdaq: CGEM) has provided a corporate update and announced its financial results for the third quarter ended September 30, 2026, showcasing significant progress across its immunology and oncology pipelines. Key milestones include advancement of velinotamig into a global study for autoimmune cytopenias, initiation of a potentially registrational Phase 2 study for CLN-049 in AML, and an NDA submission for zipalertinib in EGFR ex20ins NSCLC. The company reported $313.8 million in cash and investments, projecting a runway into 2029.

Nov 10, 2026

PMV Pharmaceuticals (PMVP) reported a net loss of $34.4 million for the third quarter of 2026, ending September 30. Despite the loss, the company holds $108.5 million in cash and completed a $50 million public offering, planning to submit a rezatapopt NDA in Q1 2027. Research and development expenses decreased year-over-year, and PMV Pharma anticipates its cash runway will last into the first quarter of 2028.

Nov 10, 2026

Tyra Biosciences (TYRA) reported a third-quarter 2026 net loss of $51.1 million, an increase from $29.9 million a year earlier, with a net loss per share of $0.74. The company concluded September with $700.5 million in cash and expects these resources to fund operations through 2030. Additionally, initial Phase 2 SURF302 results showed a 79% overall response rate, and the company anticipates more Phase 2 results and a Phase 3 study for dabogratinib in 2027.

Nov 10, 2026

Novavax (NVAX) is a trending stock due to recent investor interest, despite a -14% return over the past month. Zacks Equity Research provides insights into the company's earnings estimates, revenue growth, and valuation to help investors make informed decisions, noting its Zacks Rank #3 (Hold) suggests it may perform in line with the broader market.

Nov 10, 2026

Ardelyx Inc. (Nasdaq: ARDX) announced its participation in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, at 11:30 a.m. GMT / 6:30 a.m. ET. The company, a commercial-stage biopharmaceutical firm, will provide a live webcast of the chat accessible on its investor relations website, with a replay available afterward. Ardelyx focuses on developing and commercializing innovative medicines, including two approved products in the U.S., IBSRELA® and XPHOZAH®, and has a pipeline for chronic idiopathic constipation (CIC) and other therapeutic areas.

Nov 10, 2026

Black Diamond Therapeutics plans to initiate a 300-patient pivotal Phase 3 trial for its lung-cancer drug, silevertinib, in 2027, following positive Phase 2 results and feedback from the FDA. The trial will focus on brain-lesion response for accelerated approval and will require lower-dose safety data before commencing. The company reported a 60% overall response rate in previously untreated patients and a median progression-free survival of 15.0 months.

Nov 10, 2026

HUMACYTE ($HUMA) announced its Q3 2026 earnings, reporting -$0.07 per share, surpassing estimates of -$0.09. The company also beat revenue estimates with $1,030,000. The article details recent insider trading activity, with more purchases than sales, and provides an overview of institutional investor movements and analyst price targets for the stock.

Nov 10, 2026

Compugen (CGEN) is set to present its UnigenX platform at the 18th Annual PEGS Europe Summit on November 18, 2026, in Lisbon, Portugal. The UnigenX platform expands Compugen's computational discovery efforts into targeted immune activation, including T cell engagers, aiming to identify novel tumor-associated antigen targets for selective cancer cell targeting. The presentation, delivered by Dr. Roy Granit, Head of Computational Discovery, will highlight the platform's AI-powered capabilities for discovering new targets and combinations in cancer immunotherapy.

Nov 10, 2026

Xilio Therapeutics announced its third-quarter 2026 financial results, highlighting significant pipeline advancements. The company dosed its first patient in a Phase 1/2 clinical trial for XTX501, a PD-1/masked IL-2 bispecific, and is progressing two masked T Cell Engager programs, XTX602 and XTX701, toward IND applications in Q4 2027. Financially, Xilio reported $122.2 million in cash and cash equivalents, and a net loss of $5.9 million for the quarter, with an anticipated cash runway into Q1 2028.

Nov 10, 2026

State Street Corporation has disclosed a 4.1% beneficial ownership stake in CytomX Therapeutics Inc, holding 9,025,855 shares as of September 30, 2026. This ownership, reported via a Schedule 13G filing, involves shared voting and dispositive power through five investment adviser subsidiaries. The filing indicates that the securities were acquired in the ordinary course of business and not to influence company control.

Nov 10, 2026

Protalix BioTherapeutics Inc. reported a profit of $4 million, or 5 cents per share, in its third quarter. The drug developer achieved revenue of $21.9 million for the period and projects full-year revenue to be between $78 million and $83 million.

Nov 10, 2026

Black Diamond Therapeutics, Inc. (BDTX) reported a third-quarter loss of $10 million, or 17 cents per share, missing analyst expectations. Analysts surveyed by Zacks Investment Research had predicted a loss of 3 cents per share. The company's shares closed at $1.86, significantly down from $3.89 a year ago.

Nov 10, 2026

Black Diamond Therapeutics (BDTX) announced updated Phase 2 results for silevertinib in frontline non-small cell lung cancer, reporting a 60% tumor response and 15.0-month median progression-free survival. The FDA's feedback supports a clear path to potential accelerated approval based on an 86% brain-tumor response, and full approval through progression-free survival. The company plans to initiate a global Phase 3 trial in Q2 2027, provided safety data from the 150 mg dose cohort are submitted.

Nov 10, 2026

Several insiders at Assembly Biosciences (NASDAQ:ASMB) have sold shares over the past year, which could be a red flag for investors. While individual selling can have various explanations, a pattern of multiple insiders selling warrants attention. Notably, the biggest sale by Jason Okazaki accounted for 17% of his holding, and there have been no insider purchases recorded in the last year or three months, suggesting some insiders may not view the shares as cheap.

Nov 10, 2026

Phio Pharmaceuticals announced that clinical data from its Phase 1b trial for PH-762, an INTASYL siRNA compound, were presented at the 2026 American Society for Dermatologic Surgery Annual Meeting. The presentation highlighted PH-762's potential as a tissue-sparing neoadjuvant therapy for cutaneous carcinomas, suggesting it is well-tolerated and may reduce the extent of surgery. A Phase 2b study is planned for the first half of 2027 to further evaluate its safety and efficacy.

Nov 10, 2026

Codexis, Inc. has secured a $60 million senior secured term loan with Trinity Capital Inc., using the initial $42.5 million drawdown to refinance existing debt. This new financing provides 48 months of interest-only payments followed by a 12-month amortization, offering enhanced financial flexibility for Codexis. The company plans to use this capital to advance its growth initiatives, particularly in the siRNA therapeutic sector and the industrialization of its ECO Synthesis platform.

Nov 10, 2026

Riot Platforms Inc (NASDAQ:RIOT) shares surged nearly 5% after Jefferies upgraded the stock to "buy" with a significantly increased price target of $28, following a record 15-year lease deal with an AI developer. JPMorgan Securities also raised its price target to $28. The stock has shown strong bullish sentiment from options traders and has potential for further upside due to short covering.

Nov 10, 2026

Pictet Asset Management Holding SA reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 15.9% in the third quarter, selling 24,392 shares and now owning 129,108 shares valued at $97.24 million. Other institutional investors adjusted their positions, and company insiders, including Director Christine Poon and Kathryn Guarini, sold a significant number of shares recently. Regeneron Pharmaceuticals reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $0.94 per share.

Nov 10, 2026

Pictet Asset Management Holding SA reduced its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 16.9% in the third quarter, while other institutional investors like BlackRock Inc. and Johnson & Johnson increased their positions. Analyst sentiment remains largely positive, with a "Buy" average rating and an average price target of $166.67. The company recently reported strong quarterly earnings, beating analyst expectations for both EPS and revenue.

Nov 10, 2026

Pfizer is set to invest $650 million in a new 220,000-square-foot manufacturing technology center at its research and development campus in Groton, Connecticut. Despite this significant investment outside the state, Massachusetts economic development officials are not worried about the Bay State's ability to compete for biotech and pharmaceutical business. Pfizer maintains a substantial presence in Massachusetts with R&D and manufacturing sites in Andover and Cambridge.

Nov 10, 2026

Candriam S.C.A. significantly increased its stake in Olema Pharmaceuticals (NASDAQ:OLMA) during the third quarter, purchasing an additional 433,334 shares to bring its total holdings to 1.18 million shares valued at $10.3 million. This comes as Olema Pharmaceuticals reported a quarterly loss that missed analyst expectations, with shares trading below key moving averages. Despite varying analyst price targets, the company currently holds an average "Moderate Buy" rating.

Nov 10, 2026

Novavax reported better-than-expected revenue and adjusted EPS in Q3 2026, primarily due to a $125 million milestone payment from Sanofi for its combination vaccine trial. Despite a year-over-year sales decline, the company highlighted significant cost reductions and ongoing efforts to expand its Matrix-M adjuvant platform and pipeline. Management anticipates future performance will rely on continued partner milestones and further expense controls to achieve non-GAAP profitability by 2029.

Nov 10, 2026

ALX Oncology Holdings Inc. announced that its leadership will participate in fireside chats at three upcoming investor conferences: the UBS London Healthcare Conference on November 17, 2026, the Jefferies London Healthcare Conference on November 18, 2026, and the Piper Sandler Annual Healthcare Conference on December 1, 2026. The clinical-stage biotechnology company will discuss its pipeline, including lead therapeutic candidate evorpacept and ALX2004, a novel EGFR-targeted antibody-drug conjugate. Webcasts of the fireside chats will be available through the company's investor relations website.

Nov 10, 2026

Wall Street analysts project a 40.17% upside for Zai Lab Limited (ZLAB), with a mean price target of $37.65. While a high consensus price target doesn't guarantee stock movement, a positive trend in earnings estimate revisions and a Zacks Rank #2 (Buy) for ZLAB suggest a potential upside. Investors are cautioned to treat price targets with skepticism but consider the strong correlation between earnings estimate revisions and stock price movements.

Nov 10, 2026

Moderna (MRNA) stock has seen a significant increase of 1005.6% over the past year, prompting investors to consider trimming or adding to their positions. While the company reported a third-quarter profit in 2026 and raised its sales outlook, this profit was largely due to a strong vaccine season, with the company still operating at a loss over the full twelve months. Investors are also factoring in potential approval for a cancer vaccine in 2027, but the stock's high valuation relative to sales raises questions about its current price.

Nov 10, 2026

Atea Pharmaceuticals has secured a credit facility worth up to $200 million from Hercules Capital, with an initial $65 million received at closing. This non-dilutive financing aims to strengthen Atea's financial position and provide operational flexibility as it advances its late-stage clinical programs, including the anticipated launch of its hepatitis C virus (HCV) treatment. The funding will support the company's efforts towards key clinical and regulatory milestones, with a planned new drug application (NDA) submission in mid-2027 and potential US commercial launch in 2028.

Nov 10, 2026

Vertex Pharmaceuticals is laying off 78 employees at Crinetics Pharmaceuticals, following its $10 billion acquisition of the endocrine disease drug developer. These job cuts, affecting Crinetics' global headquarters in San Diego, are part of the integration process and are expected to take effect in January. Vertex anticipates that Crinetics' drugs, Palsonify and atumelnant, could add over $5 billion in peak annual sales.

Nov 10, 2026

Immatics N.V. (IMTX) reported a third-quarter loss of $87.5 million, translating to 58 cents per share. The Germany-based company generated $8 million in revenue for the same period. This financial summary was generated using data from Zacks Investment Research.

Nov 10, 2026

Cellectar Biosciences announced its Q3 2026 financial results, reporting a net loss of $8.0 million and cash equivalents of $24.6 million. The company provided updates on its lead drug candidate, iopofosine I 131, including positive Phase 2b data for Waldenström macroglobulinemia (WM), plans for a confirmatory Phase 3 trial, and a case study showing a complete response in diffuse large B-cell lymphoma. Cellectar aims to file for accelerated FDA approval in 1H 2027 for iopofosine I 131 in WM.

Nov 10, 2026

Xenon Pharmaceuticals (XENE) reported its Q3 2026 financial and operational results, highlighted by the submission of its New Drug Application for azetukalner in focal seizures and accelerated timelines for key clinical programs. The company maintained a strong cash position of $1.2 billion, funding operations into 2029, and discussed advancements in its epilepsy, neuropsychiatry, and pain pipelines, including positive Phase 1 data for non-opioid pain candidates. Management expressed confidence in azetukalner's commercial potential and its strategy to expand its use earlier in the treatment paradigm.

Nov 10, 2026

Black Diamond Therapeutics announced positive updated Phase 2 results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations, demonstrating robust CNS activity and an 86% CNS-ORR. The company also reported positive feedback from an End-of-Phase 2 meeting with the FDA, supporting a clear path to potential accelerated approval for silevertinib in this patient population. Black Diamond Therapeutics ended the third quarter of 2026 with $102.0 million in cash, which is expected to fund operations into the second half of 2028.

Nov 10, 2026

Wall Street analysts project a potential 379.6% upside for Cartesian Therapeutics, Inc. (RNAC), with a mean price target of $33.67. Despite the skepticism around price targets, an increasing optimism among analysts, indicated by higher EPS estimate revisions and a Zacks Rank #2 (Buy), suggests a potential upside for the stock. Investors are advised to use price targets as a starting point for further research rather than the sole basis for investment decisions.

Nov 10, 2026

This report from Stock Traders Daily analyzes Belite Bio Inc (NASDAQ: BLTE), presenting three AI-generated trading strategies for different risk profiles. It notes a neutral sentiment across all horizons, suggesting sideways action, and identifies resistance testing and a strong risk-reward short setup. The analysis provides specific entry, target, and stop levels for position trading, momentum breakout, and risk hedging strategies.

Nov 10, 2026

Monte Rosa Therapeutics presented preclinical data at ACR Convergence 2026 for MRT-8102, a NEK7-directed molecular glue degrader, demonstrating its potential in treating gout. The data showed MRT-8102 inhibited NLRP3 inflammasome activity in human experimental systems and reduced inflammation in a rabbit model of gouty arthritis. The company plans to initiate a Phase 2 GEMINI-1 study in Q4 2026, with initial data expected in H2 2027, to evaluate the prevention of recurrent flares in gout patients.

Nov 10, 2026

Passage Bio (NASDAQ:PASG) filed its Q3 2026 Form 10-Q, revealing a significant drop in cash reserves to $20.16 million from $46.30 million at the end of 2025. Total assets also decreased, and the company fully terminated its operating lease liabilities. The biotech firm also reported an increase in non-refundable sublicense payments and noted a pending merger with Remix Therapeutics, Inc.

Nov 10, 2026

Ryan Savitz, an officer at Dianthus Therapeutics, Inc., plans to sell 124,042 common shares, valued at approximately $10.67 million, which he acquired through stock option exercises. This intention was disclosed in a Form 144 filing on November 9, 2026. The sale will be executed on the NASDAQ exchange and is part of a Rule 10b5-1 trading plan adopted on August 7, 2026.

Nov 10, 2026

Immunovant reported strong Q2 2027 results, with its lead candidate IMVT-1402 demonstrating significant efficacy in a Phase 2 trial for difficult-to-treat rheumatoid arthritis. The company also announced a strategic shift away from Sjögren’s disease development due to competitor data and market changes. Roivant, the parent company, successfully launched LISRAYA, generating $31.0 million in initial revenue, and anticipates major data readouts for Graves’ disease and myasthenia gravis in 2027.

Nov 10, 2026

Surrozen, Inc. announced its financial results for the third quarter ended September 30, 2026, alongside a business update highlighting significant progress in its SZN-8141 DUET study. The company dosed its first patient in the Phase 1b portion and plans to expand Phase 2a enrollment from 60 to 150 patients to gather more robust clinical data for diabetic macular edema (DME). Financially, Surrozen secured approximately $118.9 million in net proceeds from recent financing activities, extending its anticipated cash runway into 2029.

Nov 10, 2026

Expedia (EXPE) currently allocates only 11% of its profits to dividends, suggesting substantial capacity for increasing shareholder payouts, even in the event of an earnings decline. The company primarily favors stock buybacks for returning value, having spent $1.7 billion on repurchases in 2025 compared to $200 million on dividends, with a new $5 billion authorization in place. While its low payout ratio offers dividend stability, the main risk remains the travel sector's sensitivity to economic downturns, as evidenced by Expedia's dividend suspension after 2020.

Nov 10, 2026

Mesoblast (ASX:MSB) is transitioning from an R&D focus to commercial rollout after its first product, Ryoncil, launched and generated US$115 million in sales. The company sees this as a "defining and transformative point" with further products in development for chronic low back pain and adult graft-versus-host disease. Other biotech companies, EBR Systems (ASX:EBR) and Syntara (ASX:SNT), faced challenges with sales and study setbacks, respectively, while Pathkey.AI (ASX:PKY) will use AI to evaluate Paradigm Biopharmaceuticals' (ASX:PAR) stalled knee osteoarthritis program.

Nov 10, 2026

Atea Pharmaceuticals announced strong financial health with $191.2 million in cash and a new $200 million credit facility, supporting future commercialization. Their Phase 3 trial for HCV in North America met primary and secondary endpoints, with an NDA submission anticipated by mid-2027, targeting peak U.S. net sales over $700 million. Additionally, a Phase 1 clinical trial for AT-587, a potential first-in-class treatment for chronic HEV, has begun, with a proof-of-concept study planned for early 2027.

Nov 10, 2026

Ionis Pharmaceuticals' shares dropped significantly after the company reduced its sales projections for its triglyceride-lowering drug, Tryngolza. The biotech firm now expects $50 million in sales by year-end, a substantial decrease from its initial forecast of $100 to $110 million, with third-quarter sales falling well below Wall Street expectations. Analysts suggest that doctors have been slow to prescribe the drug, leading to a 25% drop in stock value.

Nov 10, 2026

Ocular Therapeutix Inc. (OCUL) announced landmark Phase 3 superiority results for AXPAXLI in wet AMD, demonstrating durable vision maintenance and aiming for an NDA submission in Q4 2026 with a 505(b)(2) pathway. Despite a strong cash position of $530.6 million extending into 2028, the company faces scrutiny over a changed primary endpoint in the SOL-R trial and potential challenges in market adoption amidst competition, with commercialization costs not fully factored into current cash runway projections. The earnings call also provided updates on regulatory interactions, repeat-dosing data, and the commercial strategy for AXPAXLI, positioning it as a long-term maintenance therapy.

Nov 9, 2026

Aura Biosciences Inc. (NASDAQ: AURA) is showing strong sentiment across all horizons, supporting an overweight bias. AI models have generated three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop levels. The stock exhibits an exceptional 58.5:1 risk-reward setup, targeting a 16.1% gain versus 0.3% risk.

Nov 9, 2026

Coherus BioSciences reported Q3 2026 net sales of $14 million, falling short of their 10-15% target despite 25% year-over-year growth. The company announced a 30% headcount reduction to save $6-7 million quarterly and is strategically focusing its Tegmo Ketog program on esophageal cancer for accelerated FDA approval and ex-US partnerships. Coherus aims to boost LOQTORZI revenues to $25-$30 million quarterly by 2027 to cover core costs and achieve financial sustainability.

Nov 9, 2026

Neuraxis Inc (NRXS) reported record Q3 2026 revenue of $2 million, a 150% year-over-year increase, driven by expanded gross margins and new payer additions covering 147 million lives. Despite this growth, the company recorded a net loss of $6.5 million, largely due to one-time stock compensation charges, and cash on hand decreased. Management discussed strategies for resolving payer authorization issues, expanding the sales team, and achieving cash flow breakeven by early to mid-2027.

Nov 9, 2026

Trevi Therapeutics reported Q3 2026 financial results, highlighting the initiation of OCEAN-1 and OCEAN-2 trials for IPF-related chronic cough, with readouts expected in H2 2027 and H1 2028, respectively. The company also announced plans for a Phase 2 dose-ranging study for non-IPF ILD cough to begin in Q1 2027, with top-line data anticipated in H1 2028. With $299 million in cash, Trevi Therapeutics has funding into 2030, covering clinical trials and pre-commercial activities, and aims to be a leader in chronic cough therapies.

Nov 9, 2026

Immutep's shares surged by 23.81% following positive trial data for its experimental drug IMP761. The antibody drug safely suppressed immune reactions across seven dose levels in a first-in-human trial, with the company planning to release further ascending-dose data in the new year to set Phase 2 doses. IMP761 is currently the only lymphocyte activation gene-3 agonist antibody in clinical development for autoimmune conditions.

Nov 9, 2026

Larimar Therapeutics (LRMR) has completed its Biologics License Application (BLA) submission to the FDA for accelerated approval of nomlabofusp for Friedreich’s ataxia, supported by data showing sustained increases in skin frataxin. The company expects a BLA submission acceptance decision in early 2027 and aims for a U.S. launch in Q3 2027 if approved. Additionally, the article details recent insider trading activity and institutional investor movements in LRMR stock.

Nov 9, 2026

This article lists 12 healthcare stocks that experienced significant movement during Monday's after-market session. Six companies saw their stock prices increase, including Karyopharm Therapeutics and Fractyl Health, while another six, such as Tvardi Therapeutics and Acadia Pharmaceuticals, experienced declines. The movements are attributed to various factors including recent earnings reports and market capitalization changes.

Nov 9, 2026

ADC Therapeutics SA reported a loss per share of $0.06 for Q3 2026, with a net loss of $8.8 million, demonstrating ongoing investment in its antibody drug conjugate platform. Despite the loss, the company generated $21.7 million in revenue, a 32.1% increase from Q3 2025, indicating growing commercial traction for its targeted cancer treatments. Wall Street analysts maintain a generally positive outlook, with 4 buy and 3 hold ratings.

Nov 9, 2026

AN2 Therapeutics, Inc. reported a narrower loss for the third quarter of 2026, with a loss of $0.17 per share, improving 45.2% from the previous year. The company recorded a net loss of $8.0M as it continues to advance its small-molecule therapeutic pipeline. Analysts maintain a cautious but optimistic outlook, with three buy ratings and one hold rating.

Nov 9, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) reported a strong third-quarter beat in 2026, with revenue growing 55% year-over-year to $243.0M, significantly exceeding Wall Street's forecast. The company's loss per share narrowed to $0.66, and its flagship product, SPINRAZA, continued its impressive growth. Management also raised its full-year revenue guidance, leading to a positive market reaction.

Nov 9, 2026

Shares of Capricor Therapeutics (CAPR) rose 8% after its Deramiocel cardiac results from the HOPE-3 trial received the Outstanding Research Award in Pediatric Cardiology. This award adds momentum ahead of the FDA's decision on approving Deramiocel for Duchenne muscular dystrophy (DMD) by November 22. The data highlighted potential benefits on heart function and scarring in DMD patients, a disease where cardiomyopathy is the leading cause of death.

Nov 9, 2026

Over the past five years, argenx (NASDAQ: ARGX) has delivered an average annual return of 25.51%, outperforming the market by 15.47% on an annualized basis. An initial investment of $100 in ARGX stock five years ago would now be worth $312.83, highlighting the impact of compounded returns. The company currently holds a market capitalization of $58.31 billion.

Nov 9, 2026

Tiziana Life Sciences announced that its nasal foralumab significantly reduced microglial activation in patients with non-active secondary progressive multiple sclerosis (na-SPMS) during a Phase 2a trial. The 50 microgram dose demonstrated a statistically significant reduction in activation on TSPO PET imaging and both dose arms showed improvements in fatigue. These positive results, consistent with prior expanded access program data, support further development for this condition which currently lacks FDA-approved therapies.

Nov 9, 2026

Ionis Pharmaceuticals (NASDAQ: IONS) stock hit a 52-week low on Monday after the company reduced its 2026 product sales guidance for Tryngolza, a cholesterol-lowering drug, from an expected $100-$110 million down to $50 million. Despite beating Wall Street expectations for Q3 financial results and affirming its overall 2026 sales guidance, the slower-than-anticipated launch of Tryngolza for severe hypertriglyceridemia (sHTG) is impacting investor confidence. The company's leadership remains confident in Tryngolza's long-term multibillion-dollar peak sales potential, emphasizing strategic initiatives to expand its prescriber base and improve payer access.

Nov 9, 2026

Tiziana Life Sciences highlighted the consistency between positive Phase 2a INFORM-MS trial results and longer-term clinical benefits seen in its expanded access program for intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS). Key findings included a statistically significant reduction in microglial activation and clinically meaningful improvements in fatigue, mirroring observations from patients treated for up to three years. These results support foralumab's potential as the first non-invasive anti-CD3 therapy for na-SPMS, an area with no FDA-approved treatments.

Nov 9, 2026

Compugen Ltd. (CGEN) reported its Q3 2026 financial results, highlighting progress in its clinical pipeline with the completion of enrollment for the MAIA-Ovarian trial, with data expected by Q1 2027. The company's partnered programs, rilvegostomig (with AstraZeneca) and GS-0321 (with Gilead), are also advancing. Compugen introduced UnigenX to expand its target discovery into tumor-associated antigens and maintained its cash runway projection into 2029.

Nov 9, 2026

Edesa Biotech's stock (EDSA) surged 40.0% following the announcement of an exclusive collaboration and license agreement with Kyorin Pharmaceutical for paridiprubart in Japan, specifically for acute respiratory distress syndrome (ARDS). The deal includes an upfront payment of $12 million, potential milestone payments of approximately $134 million, and tiered double-digit royalties on Japan sales. This agreement, along with positive prior Phase 3 results, validates Edesa's lead program and is seen as a significant driver for investor enthusiasm.

Nov 9, 2026

Vir Biotechnology announced positive late-stage results for its experimental chronic hepatitis delta combination therapy, showing that close to half of patients achieved undetectable virus levels and normalized liver enzymes. The company plans a mid-2027 regulatory submission and is preparing for a competitive market against Gilead's Hepcludex and Mirum Pharmaceuticals' brelovitug. Vir's CEO highlighted the regimen's potential for curative treatment, which could transform the management of this lifelong infection.

Nov 9, 2026

Immunovant (NASDAQ: IMVT) shares are soaring today after the company announced positive efficacy results from a clinical trial for IMVT-1402 in patients with difficult-to-treat rheumatoid arthritis. The 600 mg dose met its primary endpoint, paving the way for regulatory discussions with the FDA. While the company will not advance IMVT-1402 further in SjD, it anticipates topline data from other registrational studies in Graves’ disease and myasthenia gravis in 2027, and chronic inflammatory demyelinating polyneuropathy in 2028.

Nov 9, 2026

Inovio Pharmaceuticals Inc. (INO) shares surged by 24.28% to $1.51, outperforming key market indexes like the NASDAQ Composite and Dow Jones Industrial Average. This strong performance ended a four-day losing streak for the stock.

Nov 9, 2026

Incyte Corp. increased its full-year 2026 sales forecast after reporting a 14% rise in third-quarter revenue to $1.56 billion, driven by growth in its dermatology and oncology businesses, which is reducing its reliance on its flagship blood cancer treatment, Jakafi. The company raised its full-year product sales guidance to between $5.21 billion and $5.30 billion, reflecting strong demand for its marketed treatments, despite a significant increase in research and development expenses due to its acquisition of Vega Therapeutics. Incyte is also advancing several late-stage development programs across blood disorders, gastrointestinal cancers, and inflammatory diseases.

Nov 9, 2026

Mereo BioPharma announced its financial results for the third quarter ended September 30, 2026, reporting a net loss of $5.9 million and cash and cash equivalents of $26.1 million, expected to fund operations into late 2027. The company highlighted ongoing regulatory interactions for setrusumab in osteogenesis imperfecta and alvelestat in alpha-1 antitrypsin deficiency-associated lung disease, with plans to initiate a Phase 3 study for alvelestat in early 2027. Research and development expenses decreased significantly due to reductions in setrusumab and alvelestat program activities.

Nov 9, 2026

Oncolytics Biotech Inc (ONCY) announced translational data regarding heavily pretreated relapsed/refractory multiple myeloma patients, which will be presented at the 68th American Society of Hematology Annual Meeting and Exposition. The company's shares are currently trading unchanged at $0.43.

Nov 9, 2026

Heron Therapeutics (NASDAQ:HRTX) stock surged on Monday after CorMedix Therapeutics (NASDAQ:CRMD) announced its acquisition of substantially all of Heron's assets for approximately $222.6 million. The deal will expand CorMedix's hospital and surgical center commercial portfolios by adding four commercial-stage therapies, including ZYNRELEF for postoperative pain. The transaction involves cash, equity terms, and potential milestone payments and royalties for Heron.

Nov 9, 2026

Viridian Therapeutics Inc. reported positive Phase 1 clinical trial results for VRDN-008, a potential subcutaneous treatment for autoimmune and rare diseases, leading to a rally in its stock. The therapy demonstrated sustained IgG antibody reduction for eight weeks, supporting a future dosing schedule of once every eight weeks. The company plans to advance VRDN-008 into pivotal development, targeting a registrational trial launch in mid-2027 for myasthenia gravis and other autoantibody-mediated autoimmune diseases.

Nov 9, 2026

Zura Bio (NASDAQ:ZURA) shares plummeted approximately 76% after its experimental drug tibulizumab failed to meet primary and key secondary endpoints in a Phase 2 trial for hidradenitis suppurativa. The company will discontinue development for this skin disease but plans to continue studies for systemic sclerosis and polymyalgia rheumatica, with results expected in 2027 and 2028, respectively. Despite the setback, Zura Bio expects its current cash and cash equivalents to fund operations through the end of 2028.

Nov 9, 2026

Marea Therapeutics announced positive results from Part A of its Phase 2b TYDAL-TIMI 78 trial for MAR001, showing significant reductions in triglycerides (39.1%-45.5%) without worsening glycemic control. The drug, a potential first-in-class ANGPTL4 inhibitor, demonstrated even greater efficacy in participants with higher baseline triglyceride levels. These findings, presented at AHA 2026 and published in NEJM, support MAR001/MAR005 as a promising treatment for severe hypertriglyceridemia, with Part B of the trial now enrolling.

Nov 9, 2026

Abeona Therapeutics reported mixed third-quarter results, exceeding earnings loss estimates but falling short on revenue. The company expanded its rare disease pipeline by acquiring ABO-801 for eosinophilic esophagitis and secured $30 million in private placement financing from institutional investors to fund its pipeline and commercial activities. Abeona plans to initiate a Phase 3 trial for ABO-801 in mid-2027 and saw an 18% sequential rise in ZEVASKYN's net product revenue.

Nov 9, 2026

Moderna raised its 2026 revenue outlook to 15-25% growth, exceeding previous expectations, following strong third-quarter sales driven by increased COVID vaccine demand and international partnerships. The company reported an earnings beat, reduced R&D expenses, and is advancing its individualized cancer therapy, intismeran, towards regulatory filing after positive late-stage melanoma data. Despite a neutral near-term earnings outlook from Zacks Rank, Moderna remains focused on commercial expansion, operating efficiency, and oncology development.

Nov 9, 2026

Trevi Therapeutics announced its third-quarter 2026 financial results and provided business updates, highlighting active enrollment in all three Phase 3 OCEAN trials for IPF-related chronic cough. The company also reported a positive meeting with the FDA for its non-IPF ILD-related chronic cough program, with a Phase 2 trial expected to start in Q1 2027. Trevi Therapeutics ended the quarter with $299.4 million in cash, projecting a cash runway into 2030 to fund key clinical milestones.

Nov 9, 2026

Atea Pharmaceuticals announced its third-quarter 2026 financial results, highlighting positive topline data from its Phase 3 C-BEYOND trial for bemnifosbuvir/ruzasvir (BEM/RZR) in Hepatitis C Virus (HCV) and progress in its Hepatitis E Virus (HEV) program. The company also secured up to $200 million in non-dilutive funding from Hercules Capital, extending its cash runway into mid-2028. Atea anticipates submitting a New Drug Application for BEM/RZR in mid-2027 based on expected C-FORWARD trial results in early 2027.

Nov 9, 2026

A Phase 3 trial revealed that Johnson & Johnson and Protagonist Therapeutics' oral therapy, Icotyde, improved psoriatic arthritis symptoms. However, analysts suggest that AbbVie's injectable Skyrizi will likely maintain market dominance due to its higher efficacy, despite Icotyde offering a convenient oral option for patients who prefer to avoid injections. While Icotyde's efficacy was positive, it did not significantly differentiate itself from Skyrizi, which generated $17.56 billion globally in 2025.

Nov 9, 2026

Moderna reported strong third-quarter revenue growth of 29% and GAAP net income of $162 million, leading to an increased full-year guidance of 15%-25% revenue growth. This performance is attributed to stable US respiratory vaccination rates, better-than-expected international vaccine partnership revenue, and a favorable US policy outlook. Consequently, Morningstar has raised its fair value estimate for Moderna to $212 per share from $163, driven by increased covid revenue expectations and larger potential market size estimates for its oncology pipeline.

Nov 9, 2026

Abeona Therapeutics reported a significant 18% increase in third-quarter 2026 ZEVASKYN revenue, reaching US$13.5 million. The company also narrowed its net loss to US$4.8 million and completed the acquisition of ABO-801, a Phase 3-ready treatment for eosinophilic esophagitis, from Ellodi Pharmaceuticals. These developments highlight Abeona's accelerating revenue growth and expansion of its treatment pipeline.

Nov 9, 2026

ImmunityBio Inc. (NASDAQ: IBRX) stock declined on Monday after reporting third-quarter earnings that missed analyst expectations, with an adjusted loss of 9 cents per share and sales of $48.84 million, both below consensus estimates. The company's net loss widened significantly due to derivative adjustments and increased R&D and SG&A expenses. Despite the financial miss, ImmunityBio announced positive final results from its ANKTIVA bladder cancer trial and received accelerated approval for ANKTIVA in Israel.

Nov 9, 2026

Bio-Techne Corporation (TECH) reported strong first-quarter fiscal 2027 results, surpassing Zacks Consensus Estimates for both adjusted earnings per share and net sales. The company also announced that its shareholders have approved the merger agreement with Merck KGaA, an important step towards the completion of the $11.3 billion acquisition expected by late 2026 or early 2027. This merger aims to strengthen their global presence and service capabilities across the life sciences value chain.

Nov 9, 2026

Jefferies believes Viridian Therapeutics' extended-acting FcRn inhibitor, VRDN-008, has best-in-class potential due to its eight-week dosing schedule, which offers a competitive advantage over existing treatments for generalized Myasthenia Gravis (gMG). The firm sees significant market share potential for Viridian, despite the 30-minute administration time using an on-body injector. Jefferies has maintained a $35 price target, projecting pivotal data by late 2029 and approval by 2031, with further opportunities in other autoimmune diseases.

Nov 9, 2026

Vir Biotechnology Inc. (NASDAQ: VIR) announced positive topline results from its pivotal Phase 3 ECLIPSE 1 study for chronic hepatitis delta, showing significant viral suppression and a favorable safety profile. The dual regimen of elebsiran and tobevibart achieved a 44% response rate for undetectable virus and alanine aminotransferase normalization at Week 48. These positive findings have led to a substantial increase in Vir Biotechnology's stock price, with plans for a global regulatory filing by mid-2027.

Nov 9, 2026

Levi & Korsinsky is investigating Bright Minds Biosciences (NASDAQ: DRUG) following a sharp selloff in its shares. The selloff occurred after the FDA placed a partial clinical hold on the Company's planned Phase 2 BMB-101 pediatric epilepsy trial, citing toxicity findings in mice and insufficient data. The law firm is investigating potential securities law violations on behalf of investors who suffered losses.

Nov 9, 2026

TG Therapeutics reported strong Q3 2026 financial results with global revenue of $260 million, driven by $233 million in U.S. Briumvi net revenue, leading the company to raise its full-year global revenue guidance to $1 billion. Strategic initiatives include potential approval for a consolidated IV initiation dose by mid-2027 and the launch of subcutaneous Briumvi in 2028, aiming to expand market share in multiple sclerosis and new indications like myasthenia gravis and treatment-resistant schizophrenia. The company emphasized its commitment to scientific innovation and disciplined capital allocation to drive long-term value creation.

Nov 9, 2026

Tiziana Life Sciences will present its intranasal foralumab program at BIO-Europe 2026 to advance partnering discussions. This comes after positive Phase 2a results in multiple sclerosis, and the company's management will hold meetings with potential strategic partners, investors, and collaborators. Discussions will also cover their broader pipeline, including treatments for Alzheimer's disease, multiple system atrophy, and ALS.

Nov 9, 2026

Roivant Sciences reported strong Q2 2027 financial results, including $31 million in net revenue from the initial commercial launch of Lysraya, indicating high demand. The company also announced significant clinical advancements, with positive data in rheumatoid arthritis, cutaneous sarcoidosis, and PH-ILD, and plans for new indications and an Investor Day in December. Management expressed optimism about the company's trajectory, driven by robust clinical data and recent developments.

Nov 9, 2026

Ocular Therapeutix reported significant progress in 2026, including successful Phase 3 results for Xpaxly (OTX-TKI) in wet AMD and plans to submit an NDA in Q4 2026 for potential accelerated approval. The company ended the quarter with $530.6 million in cash, extending its runway into 2028. Ocular Therapeutix is focusing on Xpaxly as a long-term maintenance therapy for wet AMD, distinct from existing anti-VEGF treatments, and is preparing for its potential commercial launch.

Nov 9, 2026

Capricor Therapeutics announced that new cardiac data from its HOPE-3 Phase 3 trial for Deramiocel in Duchenne muscular dystrophy received an American Heart Association pediatric cardiology research award. While the overall cardiac endpoint missed statistical significance, a prespecified subgroup of patients with cardiomyopathy showed a 2.8-percentage-point advantage in heart pumping function, and scar imaging indicated fewer newly scarred heart segments. The Biologics License Application for Deramiocel remains under FDA review with a target action date of November 22, 2026.

Nov 9, 2026

TG Therapeutics (TGTX) reported its Q3 2026 earnings, with revenues of $259.94 million, an increase of 60.7% year-over-year, surpassing the Zacks Consensus Estimate. The company also delivered an EPS of $0.35, beating the consensus estimate by 25%. Key metrics like product revenue and U.S. BRIUMVI revenue were closely watched, and the stock currently holds a Zacks Rank #1 (Strong Buy).

Nov 9, 2026

SAB Biotherapeutics, Inc. (Nasdaq: SABS) announced that its management team will participate in several upcoming investor conferences in November and December 2026, including the Jefferies Global Healthcare Conference, UBS Global Biopharma Conference, 9th Annual Evercore Healthcare Conference, and Citi Global Healthcare Conference. Samuel J. Reich, Chief Executive Officer, will be a presenter at most of these events, which will feature fireside chats and one-on-one meetings. The company is a clinical-stage biopharmaceutical firm focusing on developing fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes and other autoimmune diseases.

Nov 9, 2026

CorMedix has agreed to acquire substantially all of Heron Therapeutics' assets for $145 million in cash, 14,583,333 CorMedix shares, royalties, and potential earn-outs up to $55 million. The acquisition will expand CorMedix's presence in acute care and oncology supportive care with four commercial-stage products. The transaction is subject to Heron stockholder approval, antitrust clearance, and other customary conditions, with a $150 million senior secured loan agreement in place to help fund the deal.

Nov 9, 2026

Achieve Life Sciences, Inc. has rebranded as AchieveRx, The Quit Company, and will begin trading on Nasdaq under the new ticker symbol QUIT on November 10, 2026. The company's mission is to develop medicine, specifically cytisinicline, for quitting smoking and vaping, reflecting a focus on nicotine dependence. This change aligns with a new leadership team guiding the company from clinical development to commercial readiness, emphasizing simplicity, science, and second chances for those looking to quit.

Nov 9, 2026

Pluri Inc. announced that its PluriCDMO business has obtained ISO 9001 and ISO 13485 certifications, enhancing its ability to attract new customers in the regulated life sciences and medical device industries. These certifications validate Pluri's quality management systems and extensive manufacturing capabilities, supporting its commercial expansion efforts launched in 2024. The move positions PluriCDMO to broaden its range of services and secure more customer programs and revenue.

Nov 9, 2026

COMPUGEN ($CGEN) reported its Q3 2026 earnings, beating analyst estimates for both earnings per share and revenue. The company posted -$0.06 EPS against an -$0.08 estimate and $3.82 million in revenue, significantly exceeding the $1.734 million estimate. The article also details recent insider trading activity and institutional investor movements in CGEN stock.

Nov 9, 2026

EDITAS MEDICINE ($EDIT) reported its Q3 2026 earnings, surpassing analyst estimates for both earnings per share and revenue. The company posted -$0.15 per share, beating the -$0.19 estimate, and recorded revenue of $10,370,000, significantly exceeding the $4,549,118 estimate. The article also details recent insider trading activity, primarily sales, and significant increases in institutional holdings from various hedge funds.

Nov 9, 2026

Celcuity (CELC) reported a wider net loss and higher basic loss per share in Q3 2026, leading to a recent stock price decline despite a slight bounce after earnings. Analysts still consider the stock 56% undervalued with a fair value of $152.72, supported by recent financing that provides funding through 2027. However, the company faces risks related to heavy R&D spending, ongoing net losses, and clinical uncertainties surrounding its drug candidate, gedatolisib.

Nov 9, 2026

Foghorn Therapeutics (FHTX) reported a net income of $58.150 million for Q3 2026, a significant improvement from a net loss a year prior. This was largely driven by an $83.543 million collaboration revenue, which included a $74.1 million cumulative catch-up adjustment due to decisions not to advance two programs. The company also highlighted its strong cash position of $156.222 million, extending its cash runway into the second half of 2029, and outlined upcoming milestones for its oncology and inflammation programs.

Nov 9, 2026

Tiziana Life Sciences will present at BIO-Europe 2026 to discuss the progress of its intranasal foralumab program, particularly the positive topline results from the Phase 2a INFORM-MS trial in non-active secondary progressive multiple sclerosis (na-SPMS). The company is also hosting a KOL webcast to elaborate on these results and engage with potential partners and investors regarding its pipeline in neuroinflammatory and neurodegenerative diseases. This event provides a key opportunity for Tiziana to advance collaborations and bring its novel therapies to patients.

Nov 9, 2026

Tonix Pharmaceuticals announced its financial results for the third quarter of 2026, reporting approximately $15 million in net sales for TONMYA®, a 37% increase from the previous quarter. The company also highlighted its strong cash position of $163 million and strategic focus on expanding TONMYA's market presence, while advancing its core clinical programs for major depressive disorder, Lyme disease prevention, and kidney transplant rejection. Despite a net loss of $53.3 million for the quarter, Tonix increased its sales force and expanded payer access for TONMYA.

Nov 9, 2026

Genmab's petosemtamab, when added to Merck's Keytruda, significantly reduced the risk of death by 50% in 699 first-line head and neck cancer patients, regardless of their HPV status. This finding from the Phase 3 LiGeR-HN1 trial met both primary endpoints of overall survival and objective response rate. Analysts have hailed the results as "exceedingly positive" and "potentially practice-changing," highlighting a major milestone in treating recurrent or metastatic head and neck cancer.

Nov 9, 2026

The Invesco S&P 500 Equal Weight ETF (RSP) significantly increased its holdings on November 5, buying $976.9 million of stock with no sells. The largest new position was in Vylor Inc (VYLR), valued at $190.1 million, while it also topped up existing holdings in companies like Moderna Inc (MRNA) and PTC Inc (PTC). This activity highlights the fund's strategy and recent portfolio adjustments.

Nov 9, 2026

Kornitzer Capital Management Inc. KS increased its stake in Kymera Therapeutics, Inc. by 47.9% in the third quarter, acquiring an additional 9,870 shares to bring its total holdings to 30,490 shares valued at approximately $3.4 million. Other investment firms also expanded or initiated positions in Kymera, while the company reported a quarterly loss of $1.32 per share and revenue of $1.35 million, both falling short of analyst expectations. Despite this, analysts maintain a "Moderate Buy" consensus rating with an average price target of $139.16.

Nov 9, 2026

Celcuity Inc. announced that the FDA has accepted its supplemental New Drug Application (sNDA) for REVTORPYK™ (gedatolisib) to treat HR+/HER2-, PIK3CA mutant locally advanced or metastatic breast cancer. The FDA has assigned a PDUFA goal date of June 25, 2027, for this submission, which is based on data from the Phase 3 VIKTORIA-1 clinical trial. If approved, REVTORPYK would be available as a second-line therapy for a broader patient population, regardless of PIK3CA status.

Nov 9, 2026

GeoVax Labs, Inc. has announced a 1-for-24 reverse stock split, effective November 11, 2026, to meet Nasdaq's minimum bid price requirement. This action will reduce the number of outstanding shares from approximately 12.2 million to 508,745, while maintaining each stockholder's percentage ownership. The company's common stock will continue to trade under the symbol "GOVX".

Nov 9, 2026

Alps Advisors Inc. increased its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 34% in the third quarter, acquiring an additional 18,801 shares to bring its total holdings to 74,082 shares valued at approximately $6.5 million. Other institutional investors have also adjusted their positions in the company, with institutional investors collectively owning 47.53% of the stock. Despite recent insider selling, analysts maintain a consensus "Buy" rating for Dianthus Therapeutics, with an average price target of $128.77, and the company recently reported a narrower-than-expected quarterly loss and better-than-anticipated revenue.

Nov 9, 2026

Pluri Inc. announced that its PluriCDMO business has obtained ISO 9001:2015 and ISO 13485:2016 certifications, which are crucial for expanding its commercial reach in the regulated life sciences and medical device industries. These certifications validate PluriCDMO's quality management systems and manufacturing capabilities, enabling the company to engage a broader range of customers and pursue new projects. CEO Yaky Yanay emphasized that these certifications complement their existing cGMP-based experience and are vital for attracting customers with specific ISO qualification requirements.

Nov 9, 2026

ImmunityBio announced that its Anktiva plus BCG combination therapy met its primary endpoint in a Phase 2b trial for BCG-naïve bladder cancer patients, showing improved efficacy over BCG alone. The company, however, withheld specific response rates and detailed statistical data, although it confirmed no new safety concerns. ImmunityBio plans to submit a supplemental biologics license application to the FDA by year-end 2026 to expand Anktiva's indication for earlier treatment.

Nov 9, 2026

Latham & Watkins LLP advised the underwriters in Orchestra BioMed Holdings, Inc.'s US$75 million underwritten public offering of 15,000,000 shares of common stock at US$5 per share. The company also granted underwriters an option to purchase an additional 2,250,000 shares. The offering, expected to close on November 9, 2026, was led by a Capital Markets team from Latham & Watkins.

Nov 9, 2026

Ocular Therapeutix (NASDAQ:OCUL) reported Q3 2026 earnings that fell short of analyst expectations, with revenue decreasing 11.5% year-on-year to $12.87 million and a GAAP loss of $0.42 per share. The company's stock dropped 7.4% following the announcement, reflecting concerns about missed revenue targets and deepening losses despite optimism for future growth driven by its AXPAXLI product.

Nov 9, 2026

Tango Therapeutics reported its third-quarter 2026 financial results, highlighting significant progress in its clinical pipeline, particularly for vopimetostat in pancreatic cancer. The company presented promising Phase 1/2 data for vopimetostat in combination with daraxonrasib, showing an 82% objective response rate and 88% 9-month progression-free survival in pancreatic cancer patients. Based on these results, Tango plans to initiate a registrational Phase 3 study in the first half of 2027 and explore accelerated approval for its combination therapy in second-line pancreatic cancer.

Nov 9, 2026

Immuneering Corp Director Grant C. Bogle received stock options for 66,700 shares of Class A Common Stock at an exercise price of $3.65 per share. These options, granted on November 9, 2026, will expire on November 9, 2036, and vest in equal monthly installments over three years, beginning December 9, 2026. This transaction was disclosed in a Form 4 filing with the SEC.

Nov 9, 2026

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has announced updated clinical findings from its Phase 1/1b study of WTX-124 and Phase 1b/2 study of WTX-330, both of which are aimed at treating solid tumors. WTX-124 is a conditionally activated Interleukin-2 INDUKINE molecule, while WTX-330 is a conditionally activated Interleukin-12 INDUKINE molecule. The data was disclosed via a Form 8-K filing to the SEC and an accompanying press release on November 9, 2026.

Nov 9, 2026

Keros Therapeutics (NASDAQ:KROS) has been upgraded from a "strong sell" to a "hold" rating by Wall Street Zen, aligning with the broader analyst consensus and an average price target of $21.40. The company recently reported strong quarterly earnings, significantly beating analyst estimates with $0.70 per share and revenue of $40.01 million. Keros Therapeutics also announced a $5 million share repurchase program, indicating management's belief that the stock is undervalued.

Nov 9, 2026

Immutep Limited (ASX:IMM) shares surged 26.19% following a first-quarter FY27 update that detailed a leaner cost base and an extended cash runway into the first half of 2028. The company also addressed the setback of its TACTI-004 trial, attributing it to manufacturing-scale differences, and highlighted its growing autoimmune program with IMP761 becoming a co-priority. Future plans include a new efti trial in H2 2027 and a further root cause update at the upcoming AGM.

Nov 9, 2026

Zura Bio's shares plummeted approximately 76% after its experimental drug, tibulizumab, failed to meet primary and key secondary endpoints in a Phase 2 trial for hidradenitis suppurativa. The company has discontinued development of tibulizumab for this skin disease but plans to continue studies for systemic sclerosis and polymyalgia rheumatica. Despite the setback, Zura Bio expects its current cash reserves to fund operations through at least the end of 2028.

Nov 9, 2026

Moderna (MRNA), Xeris Biopharma (XERS), and Vir Biotechnology (VIR) shares all surged to 52-week highs on Friday. MRNA saw a more than 5% increase after strong Q3 results led to price target hikes from analysts. XERS rocketed over 16% due to Wall Street optimism and an increased 2030 revenue outlook, while VIR rallied nearly 11% amid price target increases and anticipation of expanded Phase 2 Solstice trial data.

Nov 9, 2026

Aura Biosciences filed its Q3 2026 Form 10-Q, reporting 104,074,302 shares outstanding as of November 4, 2026. The company also announced the completion of enrollment for its pivotal Phase 3 clinical trial for bel-sar, its sole drug candidate, with topline data expected in late 2027. The filing highlighted the company's reliance on bel-sar, its history of net losses, and various operational and regulatory risks.

Nov 9, 2026

Precision BioSciences, Inc. announced the pricing of its November 2026 public offering at $7.75 per share for common stock and $7.749995 for pre-funded warrants. The company expects the net proceeds, combined with existing cash and fiscal discipline, to provide a cash runway through the fourth quarter of 2029. This funding is projected to sufficiently capitalize both PBGENE-HBV and PBGENE-DMD clinical programs through key next-stage inflection points.

Nov 9, 2026

Edesa Biotech has signed an exclusive licensing agreement with KYORIN Pharmaceutical Co., Ltd. for the development and commercialization of paridiprubart in Japan, potentially worth up to $146 million. Edesa will receive an upfront payment of $12 million and is eligible for additional milestone payments and tiered double-digit royalties on net sales. Kyorin will fund all Japanese development and commercialization for paridiprubart, an investigational monoclonal antibody that demonstrated a significant reduction in 28-day mortality in a Phase 3 study for acute respiratory distress syndrome (ARDS).

Nov 9, 2026

Immutep's Phase I study for IMP761, a LAG-3 agonist antibody for autoimmune diseases, demonstrated significant, exposure-dependent suppression of T-cell responses with good tolerability across all seven dose levels. No serious adverse events were reported, building confidence for its potential to treat autoimmune conditions by targeting the root cause. Future multiple-dose data will guide the Phase II program.

Nov 9, 2026

Nurix Therapeutics experienced a significant stock decline after Sanofi terminated the development of SAR448272, a Phase I immunology candidate, despite a recent milestone payment. While Sanofi cited nonclinical findings as the reason, analysts speculate that broader portfolio strategies or data from other collaborations might have influenced the decision. Nurix maintains a strong financial position due to its collaboration with Roche on bexobrutideg, a BTK degrader with a large addressable market opportunity.